ليست عنوان مقالات لاتين 2, 3-Dihydrazone cellulose: Prospective material for tissue engineering scaffolds 2010 list of reviewers for Automatica

<< مقالات لاتين >>

<< بر اساس عنوان >>

1

2, 3-Dihydrazone cellulose: Prospective material for tissue engineering scaffolds

2

2, 4-D Dichlorophenoxyacetic Acid Poisoning; Case Report and Literature Review

3

2,000 sets of Airbus wings

4

2,1,3-Benzothiadiazole-containing donor–acceptor–acceptor dyes for dye-sensitized solar cells

5

2,1,3-Benzoxadiazole-based selective chromogenic chemosensor for rapid naked-eye detection of Hg2+ and Cu2+

6

2,15-Dihydroxy-hexahelicene (HELIXOL): synthesis and use as an enantioselective fluorescent sensor

7

2,2,2-Trifluoroethyl 6-thio-β-d-glucopyranoside as a selective tag for cysteines in proteins Original Research Article

8

2,2,2-Trifluoroethyl methacrylate-graft-natural rubber: Synthesis and application as compatibilizer in natural rubber/fluoroelastomer blends

9

2,2,3,3,11,11,12,12-Octamethyl-1,4,7,10,13-pentaoxacyclohexadecane: improved synthesis and crystal structure with NaSCN

10

2,2,3,3,6,6-Hexachlorobiphenyl Hydroxylation by Active Site Mutants of Cytochrome P450 2B1 and 2B11

11

2,2,4,4-Tetrathio substituted 1,3-dithietanes

12

2,2,6,6-Tetramethylcyclohexanethione S-methylide, a highly hindered thiocarbonyl ylide: two-step cycloadditions

13

2,2,6,6-Tetramethylpiperidine-1-yloxyl bound to the imidazolium ion by an acetamido group for investigation of ionic liquids

14

2,2ʹ:6ʹ,2ʹʹ-Terpyridine metal complexes as building blocks for extended functional metallo-supramolecular assemblies and polymers

15

2,2′-(Disulfanediyl)dibenzoic acid N,N-dimethylformamide monosolvate: crystal structure, Hirshfeld surface analysis and computational study

16

2,2′,3,3′,4,4′-Hexachlorobiphenyl subchronic toxicity in rats

17

2,2′,3,4-Tetrahydroxy-3′-sulpho-5′-nitroazobenzene for spectrophotometric determination of aluminium in pharmaceutical suspensions and granite Original Research Article

18

2,2′:6′,2″-Terpyridine and bis(2,2′:6′,2″-terpyridine)ruthenium(II) complex on the dendritic periphery

19

2,2′:6′,2″-Terpyridine complexes of molybdenum(II) and tungsten(II). X-ray crystal structures of [MoI(CO)(terpy)(η2-PhC2Ph)]I and [WI(terpy)(η2-PhC2Ph)2]I·CDCl3

20

2,2′:6′,2″-Terpyridine[hydroxypropyl-β-cyclodextrin] 1:3 complex used as chelating agent for the determination of iron with a sensitive, selective and fast liquid chromatographic method Original Research Article

21

2,2′-Azobis (4-Methoxy-2,4-Dimethylvaleronitrile), a New Lipid-Soluble Azo Initiator: Application to Oxidations of Lipids and Low-Density Lipoprotein in Solution and in Aqueous Dispersions

22

2,2′-Biphenyldiol-bridged bis(free base porphyrin): synthesis and chiroptical probing of asymmetric amino alcohols

23

2,2′-Bipyridine and related N-chelants as very effective promoters for Cu catalysts in the decarboxylation

24

2,2′-Bipyridine, 2-(2-oxazolyl)pyridine and 2,2′-bisoxazole derived nickel(0) complexes as selective catalysts for cross-coupling of aryl chlorides by intramolecularly stabilized dialkylaluminum reagents

25

2,2′-Bipyridine,1,10-phenanthroline and 2,2′:6′,2″-terpyridine in gallium(III) chemistry: Complexes containing the core

26

2,2′-Bipyridinebutyldithiocarbamatoplatinum(II) and palladium(II) complexes: Synthesis, characterization, cytotoxicity, and rich DNA-binding studies Original Research Article

27

2,2′-Bipyrimidine transition metal complexes: Synthesis, reaction chemistry and solid state structures

28

2,2′-Bis((di-tert-butylphosphino)methyl)-1,1′-biphenyl (ditbi): a bulky analogue of bisbi. The crystal structure of [Rh2Cl2(1,5-cod)2(μ-ditbi)]

29

2,2′-Bis(diarylstibano)-1,1′-binaphthyls (BINASbs); a useful chiral ligand for palladium-catalyzed asymmetric allylic alkylation, and the structure of a BINASbPdCl2 complex

30

2,2′-Diamino-6,6′-dimethylbiphenyl as an efficient ligand in the palladium-catalyzed Suzuki–Miyaura and Mizoroki–Heck reactions

31

2,2′-Diaminoazo-benzene, a potential scaffold for the synthesis of bis-ureas and thioureas: Solution phase anion sensing and binding studies

32

2,2′-Dilithiobiphenyl by direct lithiation of biphenylene

33

2,2′-dithiobisbenzamides derived from α-, β- and γ-amino acids possessing anti-HIV activities: synthesis and structure–activity relationship Original Research Article

34

2,2′-Oxydiacetato-bridged complexes containing Sm(III) and bivalent cations. Synthesis, structure, magnetic properties and chemical speciation

35

2,2′-Pyridoin derivatives protect HL-60 cells against oxidative stress

36

2,2-Bipyridine: An Efficient Ligand in the Cobalt-Catalyzed Synthesis of Organozinc Reagents from Aryl Chlorides and Sulfonates

37

2,2-Bipyrimidine- and 2,3-bis(2-pyridyl)pyrazine-containing manganese(II) compounds: structural and magnetic properties

38

2,2-Bis(3-allyl-4-hydroxyphenyl)hexafluoropropane and fluorosiloxane as coating materials for nerve agent sensors

39

2,2-Dichlorination of Aldehydes with the 2,6-Lutidine·HCl/Cl2/CH2Cl2 System: an Environmentally Benign Process Suitable for Scale Up

40

2,2-Dichlorobiphenyl Decreases Amplitude and Synchronization of Uterine Contractions Through MAPK1-Mediated Phosphorylation of GJA1 (Connexin43) and Inhibition of Myometrial Gap Junctions

41

2,2-dicyanovinyl as a nonaromatic aryl bioisostere: synthesis, binding experiments and SAR studies of highly selective dopamine D4 receptor ligands

42

2,2-Dihydroperfluoropentane (HFC 4310 mf) synthesis from HFP dimer

43

2,2-Dihydroxy-methylcyclosiloxanes and other 2,2-difunctional methylcyclosiloxanes

44

2,2-Dimethoxy-propane as electrolyte additive for lithium-ion batteries

45

2,2-Dimethyl cyclopentanones by acid catalyzed ring expansion of isopropenylcyclobutanols. A short synthesis of ((plus-minus))-(alpha)-cuparenone and ((plus-minus))-herbertene

46

2,2-Dimethyl-2-(o-nitrophenyl)acetyl (DMNA) as an assisted cleavage protecting group for amines

47

2,2-Dimethyl-2H-anthra[2,3-b]pyran-6,11-diones: a new class of cytotoxic compounds Original Research Article

48

2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors

49

2,2-Disubstituted analogues of the natural hormone 1α,25-dihydroxyvitamin D3: chemistry and biology Original Research Article

50

2,2-Hydroxyphenylbenzoxazole as a selective chelating agent for complexation with Tin and Zinc: a voltammetry study

51

2,3,4,5-Tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT2C agonists

52

2,3,5,6,7,8-Hexasilabicyclo[2.2.2]octane-1-carboxylic acids and esters: preparation and structure

53

2,3,5,6-Tetra(pyrazin-2-yl)pyrazine: a novel bis-bidentate, bis-tridentate chelator

54

2,3,5-Substituted tetrahydrofurans as cancer chemopreventives. Part 1: Synthesis and anti-cancer activities of 5-hydroxymethyl-2,3-diaryl-tetrahydro-furan-3-ols Original Research Article

55

2,3,5-Trimethylphenol oxidation over Co-based solid catalysts Original Research Article

56

2,3,5-Triphenyltetrazolium chloride (TTC) as electron acceptor of culturable soil bacteria, fungi and actinomycetes

57

2,3,6,7-Naphthalenetetracarboxylic dianhydride revisited

58

2,3,6-/3,4,5-Trimethyl substituted diaryl carotenoid derivatives (Chlorobiaceae) in petroleums of the Belarussian Pripyat River Basin

59

2,3,6-Trideoxy sugar nucleotides: synthesis and stability

60

2,3,7,8-Substituted PCDDs and PCDFs in sea lion (Otaria flavescens) skin biopsies from two South-western Atlantic populations

61

2,3,7,8-TCDD equivalence and mutagenic activity associated with PM10 from three urban locations in New Zealand

62

2,3,7,8-Tetrachlorodibenzo-p-dioxin induces a proteomic pattern that defines cleft palate formation in mice

63

2,3,7,8-Tetrachlorodibenzo-p-dioxin induces CYP1B1 expression in human luteinized granulosa cells

64

2,3,7-Trisubstituted pyrazolo[1,5-d][1,2,4]triazines: Functionally selective GABAA α3-subtype agonists

65

2,3′-disubstituted-2-(2′-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors

66

2,392 emergency department intubations: First report of the ongoing National Emergency Airway Registry study (NEAR 97)

67

2,3-Anhydrosugars in glycoside bond synthesis. Application to the preparation of C-2 functionalized α-d-arabinofuranosides

68

2,3-Anhydrosugars in glycoside bond synthesis: application to furanosyl azides and C-glycosides

69

2,3-Benzodiazepin-1,4-diones as peptidomimetic inhibitors of γ-secretase

70

2,3-Butanediol fermentation promotes growth of Serratia plymuthica at low pH but not survival of extreme acid challenge

71

2,3-Butanedione monoxime cardioplegia: advantages over hyperkalemia in blood-perfused isolated hearts

72

2,3-Dehydro-4α-hydroxylongilactone, a novel quassinoid and two known phenyl propanoids from Eurycoma longifolia Jack

73

2,3-Diamino acid modifying 3S-tetrahydroisoquinoline-3-carboxylic acids: Leading to a class of novel agents with highly unfolded conformation, selective in vitro anti-platelet aggregation and potent in vivo anti-thrombotic activity Original Research Artic

74

2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists

75

2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats Original Research Article

76

2,3-Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors

77

2,3-Diarylpyran-4-ones: a new series of selective cyclooxygenase-2 inhibitors

78

2,3-Diarylthiophenes as selective EP1 receptor antagonists

79

2,3-Dichloro-5,6-dicyano-p-benzoquinone (DDQ) as a Highly Efficient and Mild Catalyst for Diethyl Acetalization of Carbonyl Compounds

80

2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors

81

2,3-Dihydro-1H-1,3-diazepin-2-ones: synthesis and novel rearrangements into pyrrole derivatives

82

2,3-Dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran: Design and Evaluation as a Novel Radical-Scavenging Antioxidant against Lipid Peroxidation

83

2,3-Dihydro-6,7-dichloro-pyrido[2,3-b]pyrazine-8-oxide as selective glycine antagonist with in vivo activity Original Research Article

84

2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: small molecule non-peptide antagonists of the human galanin hGAL-1 receptor Original Research Article

85

2,3-Dihydrofarnesyl and citronellyl esters in the paracloacal gland secretions of the brown caiman (Caiman crocodilus fuscus) from Costa Rica

86

2,3-Dihydroimidazo[1,2-b]ferroceno[d]pyridazines and a 3,4-dihydro-2H-pyrimido[1,2-b]ferroceno[d]pyridazine: Synthesis, structure and in vitro antiproliferation activity on selected human cancer cell lines

87

2,3-Dihydroisoindolones by cyclisation and rearomatisation of lithiated benzamides

88

2,3-Dihydroxypropyl methacrylate and 2-hydroxyethyl methacrylate hydrogels: gel structure and transport properties

89

2,3-Dimercaptopropanol, 2,3-dimercaptopropane-1-sulfonic acid, and meso-2,3-dimercaptosuccinic acid inhibit δ-aminolevulinate dehydratase from human erythrocytes in vitro

90

2,3-Dimethoxy-5-methyl-1,4-benzoquinones and 2-methyl-1,4-naphthoquinones: glycation inhibitors with lipid peroxidation activity

91

2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents Original Research Article

92

2,3-Dimethyl-2,3-diphenylbutane mediated grafting of vinyltriethoxysilane to polyethylene: a novel radical initiation system

93

2,3-Di-O-methoxymethyl-6-O-tert-butyldimethylsilyl-β-cyclodextrin, a useful stationary phase for gas chromatographic separation of enantiomers

94

2,3-Di-O-methoxymethyl-6-O-tert-butyldimethylsilyl-γ-cyclodextrin: a new class of cyclodextrin derivatives for gas chromatographic separation of enantiomers

95

2,3-Diphenylpropionic acids as potent VLA-4 antagonists

96

2,3-Diphenylquinoxaline-4′,4″-dioxytriethylene glycol as a sensing and selective material for construction of strontium-PVC membrane sensor

97

2,3-Disubstituted 6-azabicyclo[3.2.1]octanes as novel dopamine transporter inhibitors Original Research Article

98

2,3-Disubstituted pyrrolo[2,3-b]quinoxalines via aminopalladation–reductive elimination

99

2,3-Disubstituted quinuclidines as a novel class of dopamine transporter inhibitors Original Research Article

100

2,3-DPG-Hb complex: a hypothesis for an asymmetric binding Original Research Article

101

2,3-Epithiopropyl methacrylate as functionalized monomer in a dental adhesive

102

2,3-Ethylene- and 2,3-trimethylene-bridged analogues of the group III metabotropic glutamate receptor ligand 2-amino-4-phosphonobutanoic acid

103

2,3-Quinoxalinedione as a novel corrosion inhibitor for mild steel in 1 M HCl

104

2,3-Substituted 2-azanorbornanes as polar β-turn mimetics

105

2,3-Unsaturated enoses. A Pummerer rearrangement route to sugar vinyl sulfides and synthesis of 3-deoxy-3-alkyl/arylsulfinyl pyranosides

106

2,4- في استحداث الكالس وتحفيز الاجنه الخضريه من زراعه البراعم D و NAA تاثير الاوكسينان بتقنيه زراعه الانسجه Ananas comosus (L.) Merr. cv. DelMonte الابطيه لنبات الاناناس

107

2,4(5)-Diarylimidazoles: Synthesis and biological evaluation of a new class of sodium channel blockers against hNav1.2

108

2,4,4,5,7,7,8,8,9,9,9-Undecafluoro-2,5-bis(trifluoromethyl)-3,6-dioxanonyl methacrylate

109

2,4,5- triarylimidazole inhibitors of IL-1 biosynthesis

110

2,4,5-Trimethoxypropiophenone from Piper marginatum

111

2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 1[]

112

2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 2[]

113

2,4,5-Trisubstituted Thiazole Building Blocks by a Novel Multi-Component Reaction

114

2,4,6,8-Tetraiodoglycoluril in sulfuric acid as a new powerful reagent for iodination of deactivated arenes

115

2,4,6-tri(3,5-Dimethylpyrazoyl)-1,3,5-triazine modified carbon paste electrode for trace Cobalt(II) determination by differential pulse anodic stripping voltammetry

116

2,4,6-Trichloro-1,3,5-triazine catalyzed synthesis of thiiranes from oxiranes under solvent-free and mild conditions

117

2,4,6-Trihydroxyacetophenone on zeolite surface: Correlation between electronic relaxation and fragmentation on mass spectra

118

2,4,6-Trimethylpyridinium perchlorate: Polar properties and correlations with molecular structure of organic–inorganic hybrid crystal

119

2,4,6-Trinitrotoluene transformation by a tropical marine yeast, Yarrowia lipolytica NCIM 3589

120

2,4,6-Trinitrotoluene Transformation Using Spinacia Oleracea: Saturation Kinetics of the Nitrate Reductase Enzyme

121

2,4,6-Triphenylphenyltellurium(IV) triiodide – supramolecular self-assembling in organotellurium triiodides

122

2,4,6-Triphenylpyrylium ion encapsulated within Y zeolite as photocatalyst for the degradation of methyl parathion

123

2,4,6-Triphenylthiapyrylium cation as homogeneous solar photocatalyst

124

2,4,6-Tris(4-iodophenoxy)-1,3,5-triazine as a new recyclable “iodoarene” for in situ generation of hypervalent iodine(III) reagent for α-tosyloxylation of enolizable ketones

125

2,4,6-Trisubstituted pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure–activity relationship Original Research Article

126

2,4,6-Trisubstituted pyrimidine derivatives as pregnancy interceptive agents Original Research Article

127

2,4,6-Tri-tert-butyl-1,3,5-triphosphabenzene as an (eta)6-Ligand in Transition Metal Complexes

128

2,4-Bis(fluorocarbon)-substituted phenols for high yield Newman–Kwart rearrangement reactions

129

2,4-Bis(methylsulfanyl)pyrimidine o-quinodimethane: a versatile building block for functionalized fused pyrimidines

130

2,4-Bis(octadecanoylamino)benzenesulfonic acid sodium salt as a novel scavenger receptor inhibitor with low molecular weight

131

2,4-Bridged 1,5-bis(fluoroalkyl)-1,3,5-triketones: synthesis and properties

132

2,4-D based herbicidal ionic liquids

133

2,4-D Exposure and risk assessment: Comparison of external dose and biomonitoring based approaches

134

2,4-Decadienal downregulates TNF-α gene expression in THP-1 human macrophages

135

2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors Original Research Article

136

2,4-Diamino-9H-pyrimido[4,5-b]indol-5-ols: Synthesis, in vitro cytotoxic activity, and QSAR investigations Original Research Article

137

2,4-Diaminopyrimidines as histamine H4 receptor ligands—Scaffold optimization and pharmacological characterization Original Research Article

138

2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase Original Research Article

139

2,4-Diaryltetrahydropyran Formation by the Prins Cyclization and Its Application towards the Synthesis of Epicalyxin F and Calyxin I

140

2,4-Diazido-5-iodo-pyrimidine crystal under high pressure: A comparison of DFT and DFT-D studies

141

2,4-Dicarboxy-pyrroles as selective non-Competitive mGluR1 antagonists: further characterization of 3,5-Dimethyl pyrrole-2,4-dicarboxylic acid 2-propyl ester 4-(1,2,2-Trimethyl-propyl) ester and structure–Activity relationships

142

2,4-Dichlorophenol (DCP) containing wastewater treatment using a hybrid-loop bioreactor

143

2,4-Dichlorophenoxy acetic acid, abscisic acid, andhydrogen peroxide induced resistance-related components against potato early blight (Alternaria solani, Sorauer)

144

2,4-Dichlorophenoxyacetic acid (2,4-D) biodegradation in river sediments of Northeast-Scotland and its effect on the microbial communities (PLFA and DGGE)

145

2,4-Dichlorophenoxyacetic acid (2,4-D) sorption and degradation dynamics in three agricultural soils

146

2,4-dichlorophenoxyacetic acid adsorption from contaminated water through activated carbon reclaimed with zero-valent iron and titanium dioxide

147

2,4-Dichlorophenoxyacetic acid degradation by catalyzed ozonation: TiO2/UVA/O3 and Fe(II)/UVA/O3 systems

148

2,4-dichlorophenoxyacetic acid-induced leaf senescence in mung bean (Vigna radiata L. Wilczek) and senescence inhibition by co-treatment with silver nanoparticles

149

2,4-Dienoyl-CoA Reductase from Escherichia coli Is a Novel Iron–Sulfur Flavoprotein That Functions in Fatty Acid β-Oxidation

150

2,4-Dimethoxyphenylsemicarbazones with anticonvulsant activity against three animal models of seizures: Synthesis and pharmacological evaluation Original Research Article

151

2,4-Dimethylphenol imprinted polymers as a solid-phase extraction sorbent for class-selective extraction of phenolic compounds from environmental water

152

2,4-Dinitro-3,5,6-trideuterophenylhydrazones for the quantitation of aldehydes and ketones in air samples by liquid chromatography–mass spectrometry

153

2,4-Dinitrophenol adsorption by date seeds: Effect of physico-chemical environment and regeneration study Original Research Article

154

2,4-Dinitrophenol and Carbonylcyanide p-Trifluoromethoxyphenylhydrazone Activate the Glutathione S-Conjugate Transport ATPase of Human Erythrocyte Membranes

155

2,4-Dinitrophenol as an activating reagent in a facile preparation of cyclic phosphate triesters

156

2,4-Dinitrophenol reduces the reactivity of Lys553 in the lower 50-kDa region of myosin subfragment 1

157

2,4-Dinitrophenol: a novel activating reagent in nucleotide synthesis via the phosphoramidite route. Design of new effective phosphitylating reagents

158

2,4-Disubstituted oxazoles and thiazoles as latent pharmacophores for diacylhydrazine of SC-51089, a potent PGE2 antagonist Original Research Article

159

2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: Synthesis and selectivity

160

2,4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors

161

2,4-Disubstituted pyrroles: synthesis, traceless linking and pharmacological investigations leading to the dopamine D4 receptor partial agonist FAUC 356

162

2,4-Disubstituted-5-acetoxythiazoles: useful intermediates for the synthesis of thiazolones and 2,4,5-trisubstituted thiazoles

163

2,4-thiazolidinediones as potent and selective human β3 agonists

164

2,5,7-Trisubstituted benzo[b]furans through a copper- and/or palladium-catalyzed assembly and functionalization process

165

2,5-Anhydro sugar diacid and 2,5-anhydro sugar diamine based C2 symmetric peptidomimetics as potential HIV-1 protease inhibitors

166

2,5-Bis(1,3-dithiol-2-ylidene)-1,3,4,6-tetrathiapentalene (TTP) derivatives having four long alkylthio chains

167

2,5-Bis-(2-hydroxybenzoylamino)pentanoic acid, a salicylic acid-metabolite isolated from chicken: characterization and independent synthesis

168

2,5-Bis-(butyltelluro) thiophene as a convenient precursor for the synthesis of 2,5-bis-(acetylenic) thiophenes

169

2,5-Bis(diphenylmethylene)-3-cyclopentenone: a solvent-dependent cobalt cluster mediated propargyl radical coupling process

170

2,5-Bis(pyridyl)pyrazine PtM, Pt2M and Ti2M2 transition metal complexes (M = Cu, Ag)

171

2,5-Bis-(sulfonyl)pyrazines as unprecedented building blocks and their SNAr reactions

172

2,5-Bis{N-(2,6-diisopropylphenyl)iminomethyl}pyrrolyl borohydride complexes of the divalent lanthanides – Synthesis, structures and ring-opening polymerization of ε-caprolactone

173

2,5-Deoxyfructosazine, a d-glucosamine derivative, inhibits T-cell interleukin-2 production better than d-glucosamine Original Research Article

174

2,5-di(thiophen-2-yl)thiazolo[5,4-d]thiazole-based donor–acceptor type copolymers for photovoltaic cells

175

2,5-Diamidofuran anion receptors

176

2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3)

177

2,5-Diarylisothiazolone: novel inhibitors of cytokine-induced cartilage destruction Original Research Article

178

2,5-Dichloro-1-(ROSO2)benzene [R = C6H5, C6F5, and CH2(CF2)4H]: Synthesis, molecular structure, and solubility in supercritical CO2

179

2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease Original Research Article

180

2,5-Difluoro-1,4-dimethoxybenzene for overcharge protection of secondary lithium batteries

181

2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor

182

2,5-dihydroxybenzo-1,3,2-dithiazolylium and 2,7-dicarbonylnaphtha-1,3,2-dithiazolylium salts and their corresponding radicals Evolution of the pseudo-1,3-dipolar cycloaddition chemistry of SNSMF6(M = As, Sb) leading to

183

2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: identification, stereochemistry and initial SAR

184

2,5-Dimethoxy-2,5-dihydrofuran and vinyl ethers in the synthesis of functionalised 2-alkylfurans

185

2,5-Dimethoxy-2,5-dihydrofuran chemistry: a new approach to 2(5H)-furanone derivatives

186

2,5-Dimethyl-4-hydroxy-2H-furan-3-one and its derivatives: analysis, synthesis and biosynthesis—a review

187

2,5-Dimethylbufotenine and 2,5-dimethylbufotenidine: novel derivatives of natural tryptamines found in Bufo alvarius toads

188

2,5-Disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists

189

2,5-Disubstituted furans from 1,4-alkynediols

190

2,5-Disubstituted pyridines: The discovery of a novel series of 5-HT2A ligands

191

2,5-Disubstituted pyrrolidine carboxylates as potent, orally active sphingosine-1-phosphate (S1P) receptor agonists

192

2,5-Di-tert-butyl-1,4-hydroquinone enhances cell transformation accompanied by an increase in intracellular free calcium ion concentration

193

2,5-Hexanedione altered the degradation of low-molecular-weight neurofilament in rat nerve tissues

194

2,5-Pyridinedicarboxylic acid derivatives as non-Nucleosidic Reverse transcriptase inhibitors of Hepatitis B Virus

195

2,6,10,15,19-Pentamethylicosenes in Methanolobus bombayensis, a marine methanogenic archaeon, and in Methanosarcina mazei

196

2,6,10-Tris(bithiophenyl)triphenylene: Synthesis and high-spin alignment in its p-doped radical derivative

197

2,6,8,9-Tetrasubstituted Purines as New CDK1 Inhibitors

198

2,6,9-Trioxabicyclo[3.3.1]nona-3,7-dien-4-oyl and tetraoxaadamantan-9-oyl functionalized aromatic di- and triamines: synthesis, stereochemistry and complexation

199

2,6,9-trisubstituted purines : Optimization towards highly potent and selective CDK1 inhibitors

200

2,6-Anhydroaldonic acids; Methyl 2,6-anhydroaldonates; 2,6-Anhydroaldonamides; Anhydroalditols; Anhydrodeoxynitroalditols

201

2,6-Bis(2-benzimidazolyl)pyridine as a chemosensor for fluoride ions

202

2,6-Bis(2-benzimidazolyl)pyridine receptor for urea recognition

203

2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays Original Research Article

204

2,6-Bis(5,6-dipropyl-1,2,4-triazin-3-yl)-pyridine: Structures of An(III) and Ln(III) 1:3 complexes and selectivity

205

2,6-Bis(benzoxazoyl)pyridine (bzpybox) as a new dialkylammonium cation receptor

206

2,6-Bis(diphenylphosphino)pyridine: a simple ligand showing high performance in palladium-catalyzed CN coupling reactions

207

2,6-Bis(porphyrin)-substituted pyrazine: a new class of supramolecular synthon binding to a transition-metal ion and fullerene (C60)

208

2,6-Cyclo-xenicanes from the brown algae Dilophus fasciola and Dilophus spiralis

209

2,6-Di(4-t-butylphenyl)phenyl-group 13 organometallic compounds

210

2,6-Di(pyrimidin-4-yl)pyridine Ligands with Nitrogen-Containing Auxiliaries: The Formation of Functionalized Molecular Clefts upon Metal Coordination

211

2,6-Diaryl-4-acylaminopyrimidines as potent and selective adenosine A2A antagonists with improved solubility and metabolic stability

212

2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A2A antagonists with reduced hERG liability

213

2,6-Diarylethynylanthracenes: synthesis, morphology, and electro-optical properties

214

2,6-Dibenzhydryl-N-(2-aryliminoacenaphthylenylidene)-4-chlorobenzenamino-palladium dichlorides: Synthesis, characterization, and use as catalysts in the Heck-reaction

215

2,6-Dibenzhydryl-N-(2-phenyliminoacenaphthylenylidene)-4-chloro-aniline nickel dihalides: Synthesis, characterization and ethylene polymerization for polyethylenes with high molecular weights

216

2,6-Dicarboxypyridinium chlorochromate: a mild, efficient, and selective reagent for oxidative deprotection of oximes to carbonyl compounds

217

2,6-Dicarboxypyridinium chlorochromate: an efficient and selective reagent for the oxidation of thiols to disulfides and sulfides to sulfoxides

218

2,6-Dichlorobenzonitrile, a cellulose biosynthesis inhibitor, affects morphology and structural integrity of petunia and lily pollen tubes

219

2,6-Difluorphenylxenon(II)bis(fluorsulfonyl)amid, -bis(trifluormethylsulfonyl)amid, -tris(fluorsulfonyl)methanid und -bis(trifluormethylsulfonyl)methanid—neue C–Xe–N- und C–Xe–C-Verbindungen?

220

2,6-Dimethoxyphenylphosphirane Oxide and Sulfide and their Thermolysis to Phosphinidene Chalcogenides—Kinetic and Mechanistic Studies

221

2,6-Dinitroaniline and β-cyclodextrin inclusion complex properties studied by different analytical methods

222

2,6-Diphenylphenolates of calcium, strontium and barium exhibiting π-phenyl encapsulation of the partially naked cations

223

2,6-Diphenylpyridine-based fluorophores: Synthesis, photophysical properties and effects of protonation

224

2,6-Diphenylpyridine-based organic emitter for electroluminescent device

225

2,6-Disubstituted N-arylsulfonyl piperidines as γ-secretase inhibitors

226

2,6-Disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK)

227

2,6-Di-tert-butyl-4-diarylmethylene- 2,5-cyclohexadiene-1-thiones. First Isolable Unannelated Thioquinone Methides

228

2,6-pyridinedicarboxylic acid as an efficient and mild organocatalyst for the one-pot synthesis of xanthene derivative

229

2,6-Pyridinedicarboxylic acid as organocatalyst for the synthesis of 1,5-benzodiazepines through one-pot reaction

230

2,6-Quinolinyl derivatives as potent VLA-4 antagonists

231

2,7-Diazabicyclo[3.3.0]octanes as novel h5-HT1D receptor agonists

232

2,7-Dihydro-3H-pyridazino[5,4,3-kl]acridin-3-one derivatives, novel type of cytotoxic agents active on multidrug-resistant cell lines. Synthesis and biological evaluation Original Research Article

233

2,7-Dimethyl-3,8-dinitrodipyrazolo[1,5-a:1′,5′-d]pyrazine-4,9-dione: A new labelling reagent for liquid chromatographic analysis of amino acids Original Research Article

234

2,7-Disubstituted proton sponges as borderline systems for investigating barrier-free intramolecular hydrogen bonds. Protonated 2,7-bis(trimethylsilyl)- and 2,7-di(hydroxymethyl)-1,8-bis(dimethylamino)naphthalenes

235

2,7-Di-tert-butyl-Fmoc-P-OSu: A new polymer-Supported reagent for the protection of the amino group

236

2,8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor Original Research Article

237

2,9-Dibromopentacene: Synthesis and the role of substituent and symmetry on solid-state order

238

2,9-Disubstituted-N6-(arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: Synthesis, biochemical and molecular modelling studies Original Research Article

239

2,μ(Ω) estimate to the mixed boundary value problem for second order elliptic equations and its application in the thermistor problem Original Research Article

240

2. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer

241

2. Changes in short afferent inhibition during phasic movement in focal dystonia

242

2. Comparison of the disinfection by-product formation potentials between a wastewater effluent and surface waters

243

2. Development and testing of an iPad application for teaching self-management to heart failure patients

244

2. Development of interictal spikes following status epilepticus from intrahippocampal pilocarpine

245

2. Dynamic analysis of EEG/MEG signals combined with fMRI

246

2. Economic assumptions underlying asian energy markets

247

2. Numerical Simulations of Water Flow and Solute Transport Applied to Acid Sulfate Soils

248

2. Pre-operative education – a review of the research design

249

2. Prognostic factors for the classification and staging of breast cancers

250

2. Receptors in HDL metabolism

251

2. Sensitized degradation of chlorophenols on iron oxides induced by visible light: Comparison with titanium oxide

252

2. Sex and intimacy among patients with implantable left-ventricular assist devices

253

2. Sleep-disordered breathing in heart failure; developing an evidence-based screening protocol

254

2. Somatosensory-evoked potential in patients with amyotrophic lateral sclerosis in a totally locked-in state

255

2. The influence of physical symptoms and mild cognitive impairment on heart failure self care

256

2. The IPC during the third revision period and beyond

257

2. THE RECONFIGURATION OF WORK AND EMPLOYMENT RELATIONS IN THE UNITED STATES AT THE TURN OF THE CENTURY

258

2. The response of a laboratory stream system to PCB exposure: study of periphytic and sediment accumulation patterns

259

2. The relationship between the satellite-based index and standard precipitation index, on different land covers

260

2.0 Å Resolution Crystal Structures of the Ternary Complexes of Human Phenylalanine Hydroxylase Catalytic Domain with Tetrahydrobiopterin and 3-(2-Thienyl)-l-alanine or l-Norleucine: Substrate Specificity and Molecular Motions Related to Substrate Binding

261

2.1 Maintaining walking direction when combining gaitwith vision distraction in young and elderly

262

2.1. Laboratory investigations in trigeminal neuralgia

263

2.10 Walking is more like catching than tapping: gait in the elderly as a complex cognitive task

264

2.11 A prospective study of older adults with a high level gait disorder: Evidence for a neurodegenerative process

265

2.1–1.85 Ga tectonic events in the Yangtze Block, South China: Petrological and geochronological evidence from the Kongling Complex and implications for the reconstruction of supercontinent Columbia

266

2.12 Gaze position, distance and postural stability in young and old subjects

267

2.13 Visual context affects postural strategies in healthy and labyrinthine deficient elderly

268

2.14 Effect of tactile ground surface indicators to the gait of elderly with normal vision

269

2.15 Age related changes in coping strategies to posturalthreat

270

2.16 Dynamic electromyographic activities of lower extremity muscles in patients with osteoarthritis of the knees

271

2.17 Dynamic control strategies used by older adults during obstacle avoidance

272

2.18 Center of mass (CoM) kinematics at slip onset and slip severity

273

2.19 The effect of age on dynamic postural equilibrium when stepping up

274

2.2 Performance based and self-reported postural control and functional correlates of stair climbing capacity

275

2.2. Spinothalamic nociceptive pathways

276

2.20 The role of vision in static posture control is age and task-dependent

277

2.21 Effects of protective equipment on the balancecontrol among younger and older firefighters

278

2.22 Postural balance in female and male subjects aged 8 to 93 years: A cross-sectional comparison

279

2.23 Effects of exercise and nutrition on Romberg quotient of postural balance in elderly with decreased bone mineral density

280

2.23 W diode-pumped Nd:YVO4/LBO Laser at 671 nm

281

2.24 The effect of postural sway on responses to anunexpected perturbation in young and elderly adults

282

2.25 Kinematic synergy adaptation to an unstable support surface and equilibrium maintenance in aging adults

283

2.26 The passive forward-push test can determine postural strategies

284

2.27 Controlling stability in challenging environments:Effects of ageing on modulation of rapid stepping reactions

285

2.28 Gaze behavior and the modulation of triggered stepping reactions to meet environmental demands in older adults

286

2.3 Vision influences on postural stability in different ages

287

2.3. Long-term depression of orofacial somatosensory processing

288

2.36 (mu)m diode pumped VCSEL operating at room temperature in continuous wave with circular TEM/sub 00/ output beam

289

2.4 GHz continuously variable ferroelectric phase shifters using all-pass networks

290

2.4 GHz direct-digital binary phase shift keying modulator using MEMS switch

291

2.4 Improving balance through imagery in frail elderly: Apilot study

292

2.4. Blink reflexes in orofacial pain conditions

293

2.41 W compact efficient CW blue light generation by intra-cavity frequency doubling of a compact Nd:YAG laser

294

2.45 GHz microwave plasma system for high-velocity thermal spraying

295

2.45 GHz synchronised polarised electron injection at MAMI

296

2.45 GHz synchronised polarised electron injection at MAMI

297

2.45-GHz-CMOS temperature compensated multi-controlled oscillator for IEEE 802.15 wireless PAN

298

2.4-in. monochrome small molecular OLED display for mobile application

299

2.5 BILLION LIVE WITH POOR SANITATION FACILITIES

300

2.5 Gbit/s silicon receiver OEIC with large diameter photodiode

301

2.5 GHz BaTiO3 DIELECTRIC RESONATOR ANTENNA

302

2.5 Kinematic and electromyographic analysis of rising from a chair during a “sit-to-walk” task in elderly subjects

303

2.5 MeV electron irradiation effect of alumina ceramics

304

2.5. The trigemino facial inhibitory reflex: Physiology, recording technique and topodiagnostic use

305

2.56-Tb/s (64*42.7 Gb/s) WDM transmission over 6000 km using all-Raman amplified inverse double-hybrid spans

306

2.5D Elastic graph matching

307

2.5D face recognition using Patch Geodesic Moments

308

2.5-D frequency-domain seismic wave modeling in heterogeneous, anisotropic media using a Gaussian quadrature grid technique

309

2.5-D gravity model of the Ni---Cu---PGM mineralized Mount Ayliff Intrusion (Insizwa Complex), South Africa

310

2.5-D Modeling in electromagnetic methods of geophysics

311

2.5D modelling of Somma–Vesuvius structure by aeromagnetic data

312

2.5-D Numerical Simulation of Acoustic Wave Propagation

313

2.5D scattering of waves by rigid inclusions buried under a fluid channel via BEM

314

2.5-Year-olds use cross-situational consistency to learn verbs under referential uncertainty

315

2.6 Å Resolution Crystal Structure of Helices of the Motile Major Sperm Protein (MSP) of Caenorhabditis elegans

316

2.6 The elderly combat to strive for better physical health

317

2.6. The role of the brain stem in central sensitisation in humans

318

2.61 (mu)m GaInAsSb/AlGaAsSb type I quantum well laser diodes with low threshold

319

2.61 Ga potassic granites and crustal reworking in the western Dharwar craton, southern India: Tectonic, geochronologic and geochemical constraints

320

2.7 Effect of age on movement amplitude and frequencyduring heel-toe rocking

321

2.7 μm fluorescence and energy transfer in Er3+ doped germanosilicate glasses

322

2.7. Bilateral brainstem activation by noxious thermal stimulation in the face

323

2.8 Å crystal structure of the malachite green aptamer

324

2.8 Challenges to whole-body stability during turning in older adults

325

2.8 Ga Old Anorogenic Granite-Acid Volcanics Association from Western Margin of the Singhbhum-Orissa Craton, Eastern India

326

2.85 µm fluorescence of Ho-doped water-free fluorotellurite glasses

327

2.9 Functional capacities evaluation during simulate working task

328

2.C.4 Dietary fatty acids and the prevention of cardiovascular disease

329

2.C.6 New strategies for drugs in atherosclerosis

330

2.E.1 Fish oil, lipids and coronary disease

331

2.Endothelin antagonists: Evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster

332

2.P.1 Selective uptake of HDL-CE by human adipose tissue is an LRP-dependent process

333

2.P.10 Effects of erythromycin on plasma fluvastatin levels: A pharmacokinetic study

334

2.P.100 The in vivo of metabolism of free-Apo(a) in normals and subjects with abetalipoproteinemia

335

2.P.101 Effect of gamma radiolysis-induced oxidation of lipoprotein(a) on plasminogen activator inhibitor (PAI-1) secretion by endothelial

336

2.P.102 Nicotinic acid decreases specifically plasma Lp(a) in cynomolgus monkeys without affecting other lipoproteins

337

2.P.103 Immunoquantification of lipoprotein (a): A comparative evaluation of four methods

338

2.P.104 Effect of continuous combined estrogen-progestin therapy on lipoprotein (a) and lipid metabolism

339

2.P.105 Apo (a) phenotypes and Lp(a) levels in acute coronary syndromes

340

2.P.106 Lp(a) and cholesterol act synergistically and predict primary myocardial infarction in Swedish males

341

2.P.107 The importance of Lp(a) as a risk factor for coronary heart disease in black and white US women

342

2.P.108 Effects of losartan on blood pressure, microalbuminuria, insulin sensitivity and lipid profile in hypertensive type II diabetics with microalbuminuria

343

2.P.109 Lack of effect of acute and chronic normalization of plasma growth hormone concentration on lipoprotein (a) levels in patients with acromegalia

344

2.P.11 Effects of atorvastatin on intracellular levels and stability of apolipoprotein B and HMG-CoA reductase in Hep G2 cells

345

2.P.110 Reduction of Lp(a) by LDL-immunoadsorption

346

2.P.111 Elevated lipoprotein (a) levels and coronary heart disease: Differences between non-insulin-dependent diabetic patients and nondiabetic subjects

347

2.P.112 Urinary excretion of lipoprotein(a) and apolipoprotein(a) in nephrotic patients

348

2.P.114 Lp(a) levels in patients with mild/moderate renal failure

349

2.P.115 Apolipoprotein(a) phenotypes as a predictor of occlusions in coronary arteries

350

2.P.116 Alcohol consumption, lipoprotein(a) and hormonal status in middle-aged black African males

351

2.P.117 Is the measurement of unbound apo(a) of diagnostic interest?

352

2.P.118 The impact of heat shock proteins as a risk factor for coronary heart disease

353

2.P.119 The KIV-10 Asp57 → Thr mutation in chimpanzee apo(a) abolishes fibrin binding

354

2.P.12 Inhibitors of hydroxymethyl glutaryl-CoA reductase as modulators of intimal thickening in diet-induced atherosclerosis

355

2.P.120 Identification of kringles of apolipoprotein(a) that enable its binding to fibrin and monocytic cells

356

2.P.121 Binding of apo(a) isoforms to fibrin is modified by their incorporation into an LDL lipoparticle

357

2.P.122 Elevated level of lipoprotein(a) and severity of coronary artery disease in non-diabetic patients

358

2.P.123 Treatment of hyperlipoproteinemia (a) with LDL-apheresis in order to stop progredient coronary heart disease: A case report

359

2.P.124 Effectiveness of the whole blood adsorber system dali in the treatment of hyperlipoproteinemia(a)

360

2.P.125 The effects of body weight loss on lipoprotein(a) in obese Japanese middle-aged women

361

2.P.126 Studies of the 5′-region of the apolipoprotein(a) gene in HepG2 cells by luciferase reporter gene assays

362

2.P.127 Red wine consumption: Another antiatherogenic effect related to decreased lipoprotein(a) levels

363

2.P.128 Recombinant apolipoprotein(a) and lipoprotein(a) enhance platelet responses to a thrombin receptor-activating peptide

364

2.P.129 Urinary excretion of apo(a) fragments in non insulin dependent diabetes mellitus patients

365

2.P.13 Effect of lovastatin in hyperlipoproteinaemic patients

366

2.P.130 Urinary excretion of apo(a) in patients after kidney transplantation

367

2.P.131 Demonstration of covalent binding of lipoprotein(a) [Lp(a)] to fibrin and human umbilical vein endothelial cells (HUVEC)

368

2.P.132 A fibrin-binding method for the functional identification of lipoprotein(a) in plasma from patients with cardiovascular disease

369

2.P.133 Lp(a) levels and apo(a) phenotypes in angiographically established coronary heart disease and in controls

370

2.P.134 Synthetic regulation of lipoprotein(a) in monkey hepatocytes

371

2.P.136 Serum lipoprotein(a) and ultrasonographic findings of carotid plaques

372

2.P.137 Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media: In vivo evidence that lipoprotein(a) may contribute to foam cell formation

373

2.P.138 Increased levels of Lp(a) in nephrotic syndrome of children is related to hypoalbuminemia, not to proteinuria

374

2.P.139 Effects of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses lpA-I and lpA-I: A-II in healthy volunteers

375

2.P.14 An overview of the clinical safety profile of atorvastatin a new, more effective HMG-CoA reductase inhibitor

376

2.P.140 Lp(a) secretion is enhanced by incubation of cynomolgus monkey hepatocytes with retinoic acid

377

2.P.141 Screening for mutations in the apolipoprotein(a) unique kringles type 6, 9 and 10

378

2.P.142 Prevalence of atherosclerotic vascular disease in the pedigrees with high Lp(a)

379

2.P.143 Lipoprotein (a) metabolism in patients with heterozygous familial hypercholesterolemia

380

2.P.144 Lp(α) levels during acute infections

381

2.P.145 Lipoprotein(a) concentration and apolipoprotein(a) isoform size in young patients with stroke

382

2.P.146 Differentiation of plasma lipoprotein (a) in a population of 1989 Greek army recruits

383

2.P.147 Lp(a) apheresis new approach for specific Lp(a) lowering

384

2.P.148 Lp(a) levels in an heterogeneous sample of subjects with familial hypercholesterolemia

385

2.P.149 Uptake of lipoprotein(a) by mouse embryonic fibroblasts via the LDL-receptor and/or the LDL receptor-related protein

386

2.P.15 Two-year comparison of safety and efficacy of atorvastatin and lovastatin

387

2.P.150 The carotid artery stenosis and the Lp(a) serum concentration: A correlation analysis

388

2.P.151 Lipoprotein(a) concentrations in subjects with one and two apolipoprotein(a) isoforms

389

2.P.152 Physical exercise decreases lipoprotein(a) levels in hyper-lp(a) diabetic patients

390

2.P.154 Lack of impaired endothelium-dependent vasorelaxation in aortas isolated from transgenic mice expressing human apolipoprotein(a)

391

2.P.155 Cholesterol esterification in hypercholesterolemic and normolipidemic subjects: Effects of simvastatin

392

2.P.156 Lipoprotein(a) levels in pulmonary arterial hypertension

393

2.P.157 Apolipoprotein(a) phenotype and serum Lp(a) levels in patients with angina pectoris and myocardial infarction

394

2.P.158 The effects of Lipoprotein (a) on endothelial function

395

2.P.159 The role of Lp(a) in the development of coronary artery disease seems to be age dependent

396

2.P.16 Fluvastatin inhibits free radical-initiated oxidation of LDL and erythrocyte hemolysis in vitro

397

2.P.160 A comparison of lipoprotein (a)-cholesterol levels and sinking prebeta lipoprol with heart disease risk in the Framingham heart study

398

2.P.161 Effect of glyated lipoprotein(a) on the production of fibrinolytic regulators in vascular endothelial cells

399

2.P.162 Relation of 5′-flanking region of the apolipoprotein(a) gene to serum lipoprotein(a) level

400

2.P.163 Localization of Lp(a) gene in human chromosomes by in situ hybridization with digoxigenin-labeled probe

401

2.P.164 Transcriptional regulation of apolipoprotein(a) synthesis by insulin

402

2.P.165 Lipoprotein(a) is a potent chemoattractant selective for human peripheral monocytes

403

2.P.166 Elevated lipoprotein(a) levels in patients with myocardial infarction are not fully determined by variation at the apo(a) gene locus. The ECTIM study

404

2.P.167 Discrepancy between whole blood and plasma concentrations of Lp(a)

405

2.P.168 Low HDL cholesterol and low lipid standardized vitamin E are the best determinants of lipid risk in our coronary patients

406

2.P.169 Detection of serum lipoprotein(a) by agarose gel electrophoresis

407

2.P.17 Effectiveness of atorvastatin in treating patients to LDL-C goals compared with lovastatin, pravastatin and simvastatin

408

2.P.170 Nandrolone decanoate reduces lipoprotein(a) levels without effect on other lipid parameters

409

2.P.171 Effect of repeated Lp(a) apheresis on metabolic parameters of lipoprotein(a)

410

2.P.172 Effect of dietary pattern on serum lipoprotein parameters in young families

411

2.P.173 Evaluation of the risk factors in coronary artery disease in Egypt. Evolving data from the national project: Lipid Profile among Egyptians (L.P.E)

412

2.P.174 Apolipoproteins and lipoprotein particles level in Moroccan patients with previous myocardial infarction

413

2.P.175 Carotid atherosclerosis and vascular risk factors in patients attending an Italian Lipid Clinic

414

2.P.176 Management of low-density lipoprotein cholesterol for secondary prevention of cardiac event after myocardial infarction

415

2.P.177 High level homocysteine, LDL modification and CHD

416

2.P.178 Smoking and transvascular leakage of albumin: Preliminary findings

417

2.P.179 Towards a cellular basis for mild hyperhomocysteinemia: Methionine metabolism in cultured human peripheral blood cells

418

2.P.18 Comparison of the efficacy and safety of atorvastatin with simvastatin in patients with primary hypercholesterolemia

419

2.P.180 Prognostic value of raised soluble thrombomodulin and soluble E-selectin in ischaemic heart disease

420

2.P.181 Lipids atherogenic factors in patients on haemodyalysis

421

2.P.182 Low density lipoprotein-associated phospholipase A2 (LDL-PLA2) as a risk factor for coronary artery disease

422

2.P.183 Microalbuminuria in dislipidaemic subjects

423

2.P.184 Fibrinolytic parameters and insulin sensitivity index related to fasting and postprandial triglyceride (TG) in healthy “normolipemic” subjects

424

2.P.185 Coronary heart disease risk factor clustering among three French regions: The WHO-MONICA population study

425

2.P.186 Influence of endurance training on susceptibility of LDL to oxidation

426

2.P.187 Methylenetetrahydrofolate reductase gene and carotid artery structural and functional characteristics in asymptomatic subjects

427

2.P.188 Pro-thrombotic effects of an acute methionine load-induced hyperhomocysteinemia in rats

428

2.P.189 Hyper-HDLemia in renal transplant recipients: Mechanisms and significations

429

2.P.19 The short-term effects of atorvastatin on lipid levels in patients with hyperlipidemia

430

2.P.190 Dyslipidaemias in children and adolescents in Portugal: A public health problem

431

2.P.191 Lipoproteins and homocysteine as risk markers for mortality in patients with coronary artery disease (CAD)

432

2.P.192 Lack of adequate risk factor management in patients with coronary artery disease

433

2.P.193 The current management of cardiovascular risk factors does not match the severity of risk factors and clinical guidelines

434

2.P.194 Coronary risk profile in Brazil

435

2.P.195 Gender differences in prediction of coronary artery disease (CAD) by plasma lipoproteins, LCAT measurements

436

2.P.196 LP(a), PAI-1 and fibrinogen are predictors of severe carotid atherosclerosis in young individuals

437

2.P.197 How many patients with coronary artery disease exhibit a significant lipid disorder in a department of cardiology in France?

438

2.P.198 Sitostanol ester added to long term simvastatin treatment of coronary patients with low and high basal cholesterol absorption

439

2.P.199 Significance of insulin like growth factor 1 for macro- and microangiopathy in non-insulin-dependent diabetes mellitus

440

2.P.2 The composition and structure of HDL regulate plasma clearance kinetics in rabbits

441

2.P.20 HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion formation in the rabbit

442

2.P.201 Does the fitness influence plasma lipoprotein levels?

443

2.P.202 Correlation between the concentrations of plasma homocysteine and vitamin B6, B12, and folate in end stage renal disease

444

2.P.203 Relation of cigarette smoking to other cardiovascular risk factors in the general population of Singapore

445

2.P.204 Homocysteine, recurrent cardiac events, and the methylenetrarahydrofolate thermolabile mutation in coronary artery disease patients

446

2.P.205 The assessment of determinants of cardiovascular risk factor clustering by multiple regression analysis

447

2.P.206 Hyperhomocysteinaemia attributes to 10 percent of all cardiovascular disease in a 50–75 year-old Caucasian population

448

2.P.207 Elevated levels of plasma homocysteine related to atherosclerotic lesions of vein grafts after coronary artery bypass grafts (CABG)

449

2.P.208 Associations between triglycerides and cholesterol levels and myocardial infarction: Results of the Tunisian study

450

2.P.21 The HMG-CoA reductase inhibitors atorvastatin and lovastatin reduce accumulation of collagenase and 92-kD gelatinase released by cultured human monocytic and vascular smooth muscle cells

451

2.P.210 Family screening as an effective tool to prevent early cardiovascular events

452

2.P.211 Plasma homocysteine levels and premature coronary artery disease in male patients

453

2.P.212 Short stature and heart disease: Nature or nurture?

454

2.P.213 Age-trends of lipid profile in Novosibirsk population

455

2.P.214 Lipid and hemostatic risk factors of coronary insufficiency in syndrome X

456

2.P.215 Hyperinsulinemia and cardiovascular mortality

457

2.P.216 To assess the changes in cardiovascular risk profile after one year of intervention at a worksite

458

2.P.217 MTHFR thermolability and vitamin status in the pathogenesis of hyperhomocysteinemia in coronary artery disease subjects

459

2.P.218 Is a fasting plasma homocysteine measurement an adequate screen for hyperhomocysteinemia?

460

2.P.219 Homocysteine and carotid artery atherosclerosis

461

2.P.22 Efficacy and safety of fluvastatin in patients with non insulin dependent diabetes on insulin therapy and dyslipidemia

462

2.P.220 Serum fibrinogen and lipoprotein(a) in a Portuguese NIDDM population

463

2.P.222 Coronary heart disease risk factors and carotid atherosclerosis in a high risk Hungarian population

464

2.P.223 Hyperfibrinogenemia and hypertriglyceridemia influence the histocytologic composition of atherosclerotic carotid plaques

465

2.P.224 Hyperhomocyst(e)inemia as an emerging risk factor of atherosclerotic vascular diseases

466

2.P.225 Effect of vitaminic therapy in hyperhomocysteinemic patients

467

2.P.226 Serum lipids in hyperhomocysteinemic patients

468

2.P.227 Frequencies of factor VII gene polymorphism and the relation to serum triglycerides in patients with chronic disease

469

2.P.228 Characteristics changes in coronary artery in patients with hypothyroidism and myocardial infarction

470

2.P.229 Hyperhomocysteinemia is a risk factor for ischemic heart disease in diabetic patients

471

2.P.23 A comparative study on the effects of fluvastatin and simvastatin on serum lipoproteins in hypercholesterolemic patients

472

2.P.230 Fractional esterification rate of cholesterol in HDL can predict the particle size of LDL and HDL in CHD patients

473

2.P.232 Lipids, LP(α) and fibrinogen in acute stroke episodes

474

2.P.233 Oxygen free radicals generation by granulocytes of patients with atherosclerosis

475

2.P.234 Risk factors for thoracic aortic atherosclerosis. A prospective study using multiplane transoesophageal echocardiography

476

2.P.235 Serum paraoxonase activity and early atherosclecrosis in hypertensive and hypercholesterolemic patients

477

2.P.236 A gas chromatography/mass spectrometry method for the quantitation of total homocysteine in human plasma

478

2.P.237 Cardiovascular risk factors in peripheral arterial disease patients with and without previous history of coronary artery disease

479

2.P.239 Lp(a) as a possible biochemical marker for vein graft stenosis after coronary artery bypass surgery

480

2.P.24 Responses to the inhibition of HMG-CoA reductase: A comparison of simvastatin and atorvastatin

481

2.P.240 Coronary heart disease risk in middle aged population - 10 year Warsaw Pol-MONICA follow-up project

482

2.P.241 Dependence between the advancement of the ischemic heart disease and the HDL cholesterol subfraction

483

2.P.243 Self-reported physical activity in healthy children is correlated with cardiovascular risk factors

484

2.P.244 Relatinship between plasma endothelin-1, HDL-C and systolic blood pressure in renal transplant recipients

485

2.P.245 Prospective randomized atherosclecrosis intervention trial in children The STRIP project

486

2.P.246 Methylentetrahydrofolate reductase genotypes in young survivors of myocardial infarction

487

2.P.247 Insulin resistance and homocystein - is there any relationship?

488

2.P.248 A prospective study of lipoprotein factors in patients with unstable angina and acute myocardial infarction

489

2.P.249 Lipoprotein metabolism in patients with coronary artery disease and its relationship with myocardial infarction

490

2.P.251 Coronary risk factors in subjects with familial hypercholesterolemia in Spain

491

2.P.252 HDL-cholesterol after surgery for aorto-coronary grafts

492

2.P.253 Common risk factors of atherosclerosis are independent from the insertion/deletion angiostensin converting enzyme gene polymorphism in subjects with coronary heart disease and healthy controls

493

2.P.254 Changes of lipid levels in Korean population

494

2.P.255 Atherosclerosis risk factors and nutrition of male students with the paternal premature myocardial infarction

495

2.P.256 Comparison of Brazilian men and women at high risk of vascular disease

496

2.P.257 Sensitivity of platelets to nitrix oxide is attenuated after vigorous exercise

497

2.P.259 Attitudes towards coronary risk factor reduction: The HELP study

498

2.P.26 Efficacy and safety of one-year treatment with slow-release nicotinic acid. Monitoring of drug concentration in serum

499

2.P.260 Independent effect of hyperglycaemia on coronary heart disease mortality among non-insulin dependent diabetic subjects: The Reykjavik study

500

2.P.261 The importance of lipid status in coronary heart disease

501

2.P.262 The assessment of risk of myocardial infarction in Moscow population

502

2.P.263 Twenty years lasting interventional study of cardiovascular risk factors in middle age men

503

2.P.264 A common mutation in methylenetetrahydrofolate reductase: Associations with homocysteine and risk of coronary atherosclerosis

504

2.P.265 Effects of androgenic anabolic steroids (AAS) on apolipoproteins and lipoprotein(a)

505

2.P.266 Serum angiotensin convertase activity in men after myocardial infarction and their healthy sons

506

2.P.268 Aging, smoking and hypercholesterolaemia have a less impact on endothelial function in the Chinese than Caucasian

507

2.P.269 Higher 7β-hydroxycholesterol in high cardiovascular risk population

508

2.P.27 Regulation of the growth kinetics of a promyelocitic leukemia cell line by hydroxymethyl glutaryl CoA-reductase

509

2.P.270 Lower oxidizability of LDL in elderly subjects with no evidence of carotid atherosclerosis

510

2.P.271 High plasma Lp(a) levels and low plasma HDL-cholesterol levels as risk factors for cerebrovascular disease in elderly men and women

511

2.P.272 Genetic risk factors in the elderly: Studies in the apolipoprotein E gene and in the methylenetetrahydrofolate reductase gene

512

2.P.273 The importance of hyperhomocysteinemia in high age people

513

2.P.275 Secondary prevention is the main basis of elderly referrals to a lipid clinic

514

2.P.276 Polymorphism of ApoAIV, apo(a) and Lp(a) plasma levels in centenarians

515

2.P.276 Polymorphism of ApoAIV, apo(a) and Lp(a) plasma levels in centenarians

516

2.P.277 One year experience with simvastatin in patients over 65 with primary hypercholesterolemia

517

2.P.278 Mild hyperhomocysteinemia correlated to folate status in Italian centenarians

518

2.P.279 Cardiovascular risks factors in a Pireness geriatric population

519

2.P.28 Preclinical drug metabolism studies in rat, mouse, dog and monkey with allometric scaling for CP-340,868, a novel squalene synthetase inhibitor

520

2.P.280 Serum sialic acid in elderly

521

2.P.285 Effects of the hormonal replacement therapy on plasma lipids in postmenopausal women with type II hyperlipidemia

522

2.P.286 Rationale and design of a trial to evaluate the impact of continuous combined hormone replacement therapy on the cardiovascular disease risk profile

523

2.P.287 Homocysteine is an independent determinant of plasma endothelin levels in healthy postmenopausal women

524

2.P.288 Postmenopausal increment of free and esterified cholesterol in the intima media of uterine arteries

525

2.P.289 Hormone replacement therapy: Can usage influence clinical outcome following coronary balloon angioplasty?

526

2.P.29 Effect of fluvastatin on plasma free-oxygen radicals (FOR) concentrations and on lipidaemic profile in patients with coronary artery disease (CAD)

527

2.P.290 Changes of lipid levels with menopause in women

528

2.P.291 Effects of tibolone on lipoproteins

529

2.P.292 The influence of menopause on LDL-subclass distributions, LDL-oxidizability and Lp(a) concentrations

530

2.P.293 Menopause aggravates postprandial lipemia

531

2.P.294 Effects of soy on lipoproteins in postmenopausal women: A double blind, multicentre, placebo-controlled trial

532

2.P.295 Does early menopause affect the risk of atherosclerosis?

533

2.P.296 The effect of hormone replacement therapy on hemostatic parameters in peri- and postmenopausal women

534

2.P.297 Lipid effects of adding C-19 versus C-21 progestin to conjugated estrogen in postmenopausal women

535

2.P.298 Current state of serum lipid levels in the general Japanese population - cholesterol and lipoprotein(a)

536

2.P.299 Effects of tamoxifen on lipid profile in postmenopausal women

537

2.P.3 Lipid-free apolipoprotein A-I can act as a shuttle to promote cholesterol efflux to apolipoprotein A-I-containng lipoproteins

538

2.P.30 Effect of fluvastatin on coagulant-fibrinolytic system in patients with coronary artery disease

539

2.P.300 Social strata and menopause caused changes in the cardiovascular risk profile

540

2.P.301 Estrogen/progestine replacement therapy improves the course of coronary artery disease in menopausal women

541

2.P.302 Smaller LDL particle size in women with polycystic ovary syndrome as compared to controls

542

2.P.303 Serum lipoprotein profile in women with coronary heart disease

543

2.P.304 17 β estradiol retard the progression of severe atherosclerosis induced by high cholesterol diet plus baloon injury: The relation of NO

544

2.P.305 Preliminary analysis of tamoxifen-induced lipemia

545

2.P.306 Hypercholesterolemia in the middle-age woman is individually a cause of ventricular arrhythmia

546

2.P.307 Gender does not predict adverse acute outcome following coronary balloon angioplasty

547

2.P.308 Lipoprotein(a), apolipoprotein E and hormonal profile in menstruating women after myocardial infarction

548

2.P.309 Effects of female sexual hormones on contractility and morphology of pre- and postmenopausal human uterine arteries

549

2.P.31 Reduction of egg yolk cholesterol content through inhibition of hepatic cholesterol biosynthesis and alteration of plasma VLDL composition in laying hens: Comparative effects of atorvastatin, lovastatin, and simvastatin

550

2.P.310 The evaluation of the atherogenic risk factors in pregnant women

551

2.P.311 Endogenous sex hormones and carotid atherosclerosis in women participating to a population-based study: Findings from Progetto Atena

552

2.P.312 Nitric oxide bioactivity in premenopausal women on hormonal contraceptives

553

2.P.313 The effect of raloxifene on markers of cardiovascular risk in healthy, post-menopausal women

554

2.P.314 Platelet aggregation induced by a monoclonal antibody to von Willebrand Factor

555

2.P.315 Simvastatin effect on platelet activity in patients with familial hypercholesterolaemia

556

2.P.316 Flow cytometry analysis of platelets in whole blood from unstable angina patients

557

2.P.317 Platelet size, β-thromboglobulin and serotonine concentration in patients with essential hypertension

558

2.P.318 Platelets count, morphology and aggregation in patients with familian hypercholesterolaemia

559

2.P.319 Effects of normothermic versus hypothermic cardiopulmonary bypass on cytokine production and platelet function

560

2.P.32 Comparison of cerivastatin and gemfibrozil in the treatment of primary mixed hyperlipidemia

561

2.P.320 Alkyl phosphatidylcholine core aldehydes exist in human atheromas and induce platelet aggregation through PAF receptor

562

2.P.321 Smoking, platelets and risk of thrombosis

563

2.P.322 The influence of butter and vegetable oil loadings on the state of thrombocyte membranes in patients with ischemic heart disease (IHD)

564

2.P.323 Structural and functional organisation of thrombocyte membranes in patients with ischemic heart disease (IHD) depending on menʹage

565

2.P.324 Immunolocalization of blocked and unblocked GP IIb-IIIa complexes in platelets during antithrombotic therapy with c7E3 Fab (ReoPro, abciximab)

566

2.P.325 CD36 is a specific platelet receptor for native and modified low-density lipoproteins

567

2.P.326 Short-term heterologous desensitization of platelet LDL receptor by high lipoprotein levels

568

2.P.326 Thyroid hormones as a determinant of plasma D-dimers levels in hyperlipidemic patients

569

2.P.327 Platelet αIIb-β3 integrin or glycoprotein (GP) IIb-IIIa complex are not related to platelet HDL3 binding

570

2.P.328 Long-term desensitization of platelet LDL receptor by high VLDL levels. Effects of gemfibrozil treatment

571

2.P.329 Hydrogen peroxide involvement in platement activation induced by collagen

572

2.P.33 Long-term extension of the comparison of cerivastatin and gemfibrozil in the treatment of primary mixed hyperlipidemia

573

2.P.330 Platelet behavior in whole blood with enhanced HDL concentration

574

2.P.331 The ADP-activated non selective cation channels may have a role in platelet aggregation

575

2.P.332 Relationship between reduction of plasma cholesterol and increased platelet activity in hypercholesterolemia

576

2.P.333 Evidence for th erole of adenosine diphosphate in platelet aggregation by remnant like lipoprotein particles of human plasma very low density lipoproteins and chylomicrns

577

2.P.334 ADP induces transient refractoriness of platelet adhesion to subendothelium under flow conditions

578

2.P.335 Colony-forming units-megakaryocytes (CFu-MEG) and primary hyperlipidemia

579

2.P.336 Native microaggregates and spontaneous platelet aggregation may present a platelet susceptibility leading to thrombogenesis - detection with an original method using a novel platelet aggregometer employing a laser light scattering

580

2.P.337 Secretion of PAF-acetylhydrolase activity during platelet aggregation in patients undergoing coronary angioplasty

581

2.P.338 Role of homocyst(e)ine in platelet aggregation

582

2.P.339 Impaired inhibition by insulin of ADP-induced expression of platelet fibrinogen receptor in NIDDM patients

583

2.P.34 Long-term efficacy and safety of a combined fluvastatin-fenofibrate therapy in primary hypercholesterolemia

584

2.P.340 Inhibition of the procoagulant activity of thromboplastin by apolipoprotein B-100

585

2.P.341 Effect of dietary saturated, oleic and n-3 fatty acids on acute collagen-induced thrombus formation in rats

586

2.P.342 Effect of policosanol on platelet aggregation and serum levels or arachidonic acid metabolites in healthy volunteers

587

2.P.343 Fluvastatin reduces platelet activity in vitro

588

2.P.344 Platelet function in hypercholesterolemia - importance of combine hyperlipidemia

589

2.P.345 The role of the C-terminal of tissue factor pathway inhibitor (TFPI) in inhibition of the extrinsic pathway of coagulation

590

2.P.347 Plasminogen activator inhibitor-1 in human fat: Effect of tumor necrosis factor-α and pentoxifylline

591

2.P.348 Alpha fibronogen genotype is associated with the porosity and density of the fibrin gel matrix in MI patients

592

2.P.349 Protein S deficiency as an additional risk factor for juvenile TIA

593

2.P.35 Lipid-lowering effect of atorvastatin in homozygous familial hypercholesterolemia patients with portocaval anastomosis

594

2.P.350 A therapeutic dosage (3 g/day) of borage oil supplementation has no effect on platelet aggregation in healthy volunteers

595

2.P.351 Lysophosphophatidycholine inhibits tissue factor expression

596

2.P.352 Low or medium dose acetylsalicylic acid increases fibrin gel porosity is healthy adults

597

2.P.353 PAI-1 genotype, PAI-1 level and risk of thrombotic complications after renal transplantation

598

2.P.354 The factor V leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients

599

2.P.355 Protease-activated receptor genes are clustered on 5q13

600

2.P.356 Fibrinogen synthesis in chronic smokers is significantly reduced after short-term cessation from smoking

601

2.P.357 The effects of physiological meals containing structured triglycerides with different fatty acid compositions on postprandial haemostasis

602

2.P.358 Prognostic value of haemorheological, haemostatic and fibrinolytic changes in progressing of cerebrovascular disorders

603

2.P.359 Is plasma fibrinogen before heart transplantation an independent predictor of graft vessel disease?

604

2.P.36 The efficacy of once-nightly niacin (Niaspan) on lipoproteins in dyslipidemic patients

605

2.P.360 Lipo-Merz reduces levels of fibrinogen and factor VII in patients with arterial hypertension

606

2.P.361 Nicotinic acid lowers P-fibrinogen and stimulates fibrinolysis!

607

2.P.363 Effects of long term administration of eicosapentaenoic acid on serum levels of tissue plasminogen activator and its inhibitor

608

2.P.364 Myocardial fibrin deposits in first month after transplantation predict subsequent coronary artery disease in cardiac allograft recipients

609

2.P.365 Coronary heart disease is associated with alterations in the daytime fluctuation pattern of plasminogen activator inhibitor 1 levels both in non-insulin-dependent diabetes patients and in nondiabetic subjects

610

2.P.366 High prevalence of homozigosity for the 677C → T mutation of the 5;10-methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in patients with early-onset thrombotic events

611

2.P.367 Protection of exercise induced pro-thrombosis by aspirin

612

2.P.368 Factor VII: A responds to fatty meals, independently of fat composition

613

2.P.369 Procoagulant factors and cholesterol

614

2.P.37 Fenofibrate decreases the fibrinogen contents depending on its basal plasma levels in patients with hyperlipidemia

615

2.P.370 Effect of simvastatin treatment on thrombin generation in marked hypercholesterolemia

616

2.P.371 In vivo thromboxane/prostacyclin balance unfavourable affected in humans after diets rich in stearic acid or trans fatty acids

617

2.P.372 Contribution of fibrinogen to elevated plasma viscosity in patients with familial hypertriglyceridemia

618

2.P.373 Different effects of wine and red wine polyphenols on PAI-1 in healthy men

619

2.P.374 Changes of blood rheology by lipid oxidation as risk factor for thrombosis

620

2.P.375 Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex

621

2.P.376 Effect of hirulog-1 on fibrinolysis and platelet deposition

622

2.P.377 Collagen-targeted antibodies could prevent acute thrombosis following PTCA

623

2.P.378 Correlation of haemostatic variables and structural changes of major arteries of the head in ischemic stroke patients

624

2.P.379 D-Dimers and fibrinogen in patients with left ventricle-dysfunction after myocardial infarction and in generalized atheriosclerosis

625

2.P.38 Long-term effects of low dose Omacor® in patients with severe hypertriglyceridemia

626

2.P.380 GPIIbIIIa inhibitors reduce procoagulant activity of platelet-derived microparticles (MP) by inhibiting their formation but not binding to fibrin(ogen)

627

2.P.381 A common mutation (G−455 → A) in the β-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study

628

2.P.382 Fibrinolytic indicators inplasma and the generation of vascular plasmin in human arteriosclerosis

629

2.P.383 Aspirin-like effects of wine polyphenols on platelet aggregation in healthy men

630

2.P.39 Effect of bezafibrate on atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance

631

2.P.4 Expression of the human phospholipid transfer protein by the yeast Pichia pastoris

632

2.P.40 Discovery of the squalene synthetase inhibitor CP-340,868

633

2.P.41 Two year treatment experience with high dose atorvastatin

634

2.P.42 An overview of the clinical efficacy profile of atorvastatin

635

2.P.43 Mechanisms of pravastatin effects on plasma lipoprotein subfractions, estimated by activities of LCAT, CETP and lymphocyte LDL-receptor

636

2.P.44 Can fluvastatin be effectively used in the treatment of combined hyperlipidemia?

637

2.P.45 Targeting high risk patients with hypercholesterolemia: The efficacy and safety of simvastatin 80 mg/d

638

2.P.46 Associations of changes in blood lipids and hemostatic factors during fenofibrate treatment in dyslipidemic patients with polymetabolic syndrome (PMS)

639

2.P.47 Is there an effect of defined molecular defect on therapeutic response to HMG Co A reductase inhibitors in patients with familial hypercholesterolaemia?

640

2.P.48 Lipid-regulating effects of new classes of squalene epoxidase inhibitors

641

2.P.49 KY-455, a new bioavailable ACAT inhibitor with anti-peroxidative activity

642

2.P.5 In vitro factors affecting the concentration of gamma-LpE (γ-LpE) in human plasma

643

2.P.50 Niacin, by inhibiting both fatty acid synthesis and triacylglycerol formation, augments apo B degradation in Hep G2 cells

644

2.P.51 Escape phenomenon during the long-term administration of pravastatin for phyperlipideia associated with diabetes

645

2.P.52 Comparison of type II hyperlipoproteinemic patients with apoprotein E2, E3, and E4 phenotypes with respect to the response of plasma levels of lipids and apoproteins to simvastatin

646

2.P.53 Effects of long-term (for 5 years) treatment using pravastatin sodium on hyperlipidemia in diabetics

647

2.P.54 A two-year intensive lipid lowering in patients with familial hypercholesterolemia

648

2.P.55 ACAT inhibition by CI-1011 lowers plasma triglycerides in rats by enhancing the clearance of VLDL

649

2.P.56 Ciprofibrate in the treatment of hypertensive postmenopausal women with hyperlipidaemia IIa

650

2.P.57 Effect of atorvastatin on key enzymes regulating lipid metabolism in the cholesterol/coconut oil fed rabbit

651

2.P.58 Effects of atorvastatin on endothelium-dependent relaxations and contractions in dyslipidemic rabbits

652

2.P.59 Efficacy and safety of cerivastatin, a novel potent HMG-CoA reductase inhibitor, in primary hypercholesterolaemia: A comparative study

653

2.P.6 Mutations of the branchpoint concensus sequence of intron 4 of lecithin: Cholesterol acyltransferase (LCAT) gene

654

2.P.62 Effect of eicosapentaenoic acid in combination with HMG-CoA reductase inhibitor on lipid metabolism

655

2.P.64 Biopharmaceutical profile of cerivastatin, a novel HMG-CoA reductase inhibitor

656

2.P.65 Stimulation of bile acid production by the ACAT inhibitor HL-004

657

2.P.66 Dose-related reduction of LDL-cholesterol in patients with primary hypercholesterolemia by atorvastatin

658

2.P.67 Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin

659

2.P.68 Difference in effect of simvastatin on DNA synthesis among cultured human cell types

660

2.P.69 Effect of itraconazole on serum concentrations of simvastatin and pravastatin

661

2.P.7 Age-related decline in plasma CETP and CETP mRNA expression in human adipose tissue

662

2.P.70 Effect of policosanol on smooth muscle cell proliferation in the cuffed carotid artery of the rabbit

663

2.P.71 NK-104, a potent HMGCoA-reductase inhibitor, increases intracellular degradation of apo B-100 and decreases its secretion in HepG2 cells

664

2.P.71 NK-104, a potent HMGCoA-reductase inhibitor, increases intracellular degradation of apo B-100 and decreases its secretion in HepG2 cells

665

2.P.72 Atorvastatin inhibition of NF-βB activation in vascular smooth muscle cells is mediated by protein isoprenylation blockade

666

2.P.74 Efficacy and safety of ciprofibrate and lovastatin in treatment of hyperlipidemia

667

2.P.75 Long-term effects of pravastatin in cyclosporine treated heart recipients

668

2.P.76 Fluvastatin or bezafibrate alone versus their combination

669

2.P.77 Lipid-lowering therapy in secondary prevention by Swiss primary care physicians: How far are we from the target values?

670

2.P.78 Factors associated with non-use of lipid-lowering drugs in secondary prevention of coronary heart diseases. EUROASPIRE study

671

2.P.79 Cholesteryl ester storage disease: Molecular defects and treatment with the HMGCoA-reductase inhibitor lovastatin

672

2.P.8 Expression of CETP mRNA by stromal vascular cells of human adipose tissue

673

2.P.80 Effects of cerivastatin 0.3 mg daily compared to 0.15 mg in patients with hypercholesterolemia

674

2.P.81 Limitation of heart growth in neonatal piglets by simvastatin but not pravastatin

675

2.P.82 Effect of atorvastatin vs. simvastatin in patients undergoing regular LDL-apheresis (ASLA I)

676

2.P.83 Effect of simvastatin on cholesterol homeostasis in hamsters fed a sucrose-rich lithogenic diet

677

2.P.84 Effect of simvastatin on hepatic cholesterol metabolism and biliary lipids in Australian gallstone patients

678

2.P.85 Cholesterol-independent effects of pravastatin on atherosclerotic plaque stability in primates

679

2.P.86 Effects of silymarin and silybin on lipoprotein cholesterol levels and oxidizability of low density lipoprotein in rats

680

2.P.87 Reduction of oxysterol levels up-regulates HMG-CoA reductase activity in rat liver

681

2.P.87 Reduction of oxysterol levels up-regulates HMG-CoA reductase activity in rat liver

682

2.P.88 Fluvastatin in higher dosage reduces also triglyceride rich lipoproteins

683

2.P.89 Effect of four week long treatment with fenofibrate on the level of 7-ketocholesterol in hyperlipidemic patients

684

2.P.9 Reduced plasma HDL-cholesterol levels in visceral obesity: Contribution of the CETP gene TaqIB polymorphism

685

2.P.91 Effect of Lifibrol on the metabolism of LDL-apo B and apo A-I in moderate hypercholesterolemia

686

2.P.92 Effect of MCC-134, a novel antihypertensive agent, on lipid metabolism and vascular smooth muscle cell proliferation in rats

687

2.P.93 Influence of lifibrol therapy on apoB metabolism in mixed hyperlipidemia and hypercholesterolemic patients

688

2.P.93 Influence of lifibrol therapy on apoB metabolism in mixed hyperlipidemia and hypercholesterolemic patients

689

2.P.94 Reduction of plasma cholesterol levels and inhibition of smooth muscle cell (SMC) proliferation by cerivastatin sodium, a new HMG-CoA reductase inhibitor

690

2.P.95 Effect of simvastatin and theofibrate on lipid and lipid peroxidation in type II hypercholesterolemic patients

691

2.P.96 The use of Acipimox as second line drug in severe hypertriglyceridemia and combined hyperlipidemia patients

692

2.P.97 Relation of lipoprotein Lp(a) concentration and apolipoprotein apo(a) phenotypes to the presence and severity of carotid atherosclerosis

693

2.P.98 Predictive value of lipoprotein(a) for peripheral vascular disease in a community-based cohort

694

2.P.99 A novel kringle-4 number-based recombinant apo(a) standard for human Lp(a) phenotyping

695

2.S.1 Atherothrombosis in the heart and brain: New insights into the role of plasma lipoproteins

696

2.W10.1 Regulation of apoptosis in vascular smooth muscle cells

697

2.W11.4 Comparison of risk factor levels in Framingham Cohort and Offspring participants

698

2.W11.5 Cardiovascular risk factors in coronary patients across Europe

699

2.W12.4 Percutaneous arterial gene therapy for the prevention of restenosis

700

2.W12.5 Adventitial gene transfer to rabbit carotid arteries

701

2.W13.1 Molecular genetics as tools to redefine the clinics of lipoprotein disorders: The example of lipoprotein lipase deficiency

702

2.W13.5 FDB-100: Diagnosis, laboratory and clinical findings, possibilities of treatment. Experience from homozygous and heterozygous patients

703

2.W14.2 Chronic plaque growth or acute rupture? The yin and yang of vascular connective tissue remodelling

704

2.W15.1 Different approaches to the detection and quantification of triglyceride-rich lipoprotein remnants

705

2.W15.4 Effect of triglyceride-rich lipoproteins on cholesterol transport and atherosclerosis

706

2.W15.5 Familial combined hyperlipidemia (FCH): Causes and consequences

707

2.W16.1 Hormonal replacement therapy of menopause and atherosclerosis

708

2.W16.3 Hormone replacement therapy, thrombosis, and haemostasis

709

2.W16.4 The impact of HRT on selected vascular and metabolic risk factors for atherosclerosis

710

2.W16.5 Hormonal agents used in lowering lipoprotein(a)

711

2.W17.1 Structural and functional consequences of non-enzymatic glycation of apolipoprotein A-I and its impact on the reverse cholesterol transport

712

2.W17.2 Caveolin-dependent free cholesterol efflux — major regulatory pathway in peripheral cells

713

2.W17.4 HDL and cellular cholesterol efflux

714

2.W17.5 Genetic determinants of HDL and their relationships to atherosclerosis

715

2.W18.1 Cellular metabolism of triglyceride-rich lipoproteins

716

2.W18.2 The effect of leukaemia inhibitory factor on experimental atherosclerosis

717

2.W18.3 Lipoprotein association with cells and matrix: Modulation by lipase and proteoglycans

718

2.W18.4 Arterial-wall sphingomyelinase and atherogenesis

719

2.W18.5 Lipid oxidation products as regulators of macrophage function in atherosclerosis

720

2/3 A-size rechargeable battery employing LiCoO2 thin-film cathode

721

2: External Validation of the Mortality in Emergency Department Sepsis (MEDS) Score: A Multi-Center Prospective Cohort Study

722

2: Hydrothermal ore deposits related to post-orogenic extensional magmatism and core complex formation: The Rhodope Massif of Bulgaria and Greece

723

2: Radiographs Versus CT for the Initial Diagnosis of Blunt Cervical Spine Injury: A Prospective Comparison

724

2:1 Atrioventricular Block During Atrioventricular Node Reentrant Tachycardi

725

2:1 Atrioventricular block: Order from chaos

726

2:1 Ba/Ti(IV) Heterobimetallic complex based on two calix[6]arenes

727

2-[(1E)-({[(Benzylsulfanyl)methanethioyl]amino}imino)methyl]-6-methoxyphenol: crystal structure and Hirshfeld surface analysis

728

2-[(1E)-[(Z)-2-({[(1Z)-[(E)-2-[(2-Hydroxyphenyl)methylidene]hydrazin-1-ylidene]({[(4-methylphenyl)methyl]sulfanyl})methyl]disulfanyl}({[(4-methylphenyl)methyl]sulfanyl})methylidene)hydrazin-1-ylidene]methyl]phenol: crystal structure, Hirshfeld surface analysis and computational study

729

2-[(2,4,6-Trimethylbenzene)sulfonyl]phthalazin-1(2H)-one: crystal structure, Hirshfeld surface analysis and computational study

730

2-[(4-Chlorophenyl)selanyl]-3,4-dihydro-2H-benzo[h]chromene-5,6-dione: crystal structure and Hirshfeld analysis

731

2-[(8-Dimethylaminonaphthalen-1-yl)dimethylsilyl]-N,N,4,4-tetramethyl-1,2,3,3a,4,5-hexahydro-4-sila-5,9b-ethenobenz[e]inde-9-amine. An unexpected by-product from the reaction of 1-lithio-8-dimethylaminonaphthalene with chlorodimethylvinylsilane

732

2-[(Alkylsulfonyl)oxy]-6-substituted-1H-isoindole-1,3(2H)-dione mechanism-based inhibitors of human leukocyte elastase

733

2-[(Diphenylphosphino)methyl]-6-methylpyridine (PN) coordination chemistry at triosmium clusters: Regiospecific ligand activation and DFT evaluation of the isomeric Os3(CO)10(PN) clusters

734

2-[(R-phenyl)amine]-1,4-naphthalendiones as photosystem I electron acceptors. Structure-activity relationship of m- and p-PAN compounds with QSAR analysis

735

2-[(substituted)phenyl]-5-[1-(2-phenylazacycloheptyl)methyl]-1H-pyrroles with high affinity and selectivity for the dopamine D3 receptor

736

2-[1-(2,6-Dibenzhydryl-4-chlorophenylimino)ethyl]-6-[1-(arylimino)ethyl]pyridyliron(II) dichlorides: Synthesis, characterization and ethylene polymerization behavior

737

2-[1-(2,6-dibenzhydryl-4-chlorophenylimino)ethyl]-6-[1-aryliminoethyl]pyridyl cobalt dichlorides: Synthesis, characterization and ethylene polymerization behavior

738

2-[1-(2,6-Dibenzhydryl-4-methylphenylimino)ethyl]-6-[1-(arylimino)ethyl]pyridylnickel(II) halides: Synthesis, characterization and ethylene oligomerization behavior

739

2-[18F]-Fluoro-2-deoxy-d-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx

740

2-[18f]-Fluoro–2-deoxy-d-glucose positron emission tomography in the evaluation of breast lesions and axillary involvement: a comparison with mammography and histopathological diagnosis

741

2-[18F]-fluoroisonicotinic acid hydrazide: biological evaluation in an acute infection model

742

2-[2-(4-Methoxyphenyltelluro)ethyl]thiophene (L1) bis[2-(2-thienyl)ethyl] telluride (L2) and their metal complexes; crystal structure of trans-dichlorobis{2-(2-(4-methoxyphenyltelluro)ethyl)thiophene-Te}palladium(II) and {bis[2-(2-thienyl)ethyl] telluride

743

2-[4-(Dimethylamino)phenyl]-3-hydroxy-4H-chromene-4-one: A H-bond-sensitive fluorescent probe for investigating binary mixtures of organic solvents Original Research Article

744

2-[4-(o-methoxyphenyl)piperazin-1-ylmethyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine as a new selective 5-HT1A receptor ligand

745

2-[Carbamothioyl(2-hydroxyethyl)amino]ethyl benzoate: crystal structure, Hirshfeld surface analysis and computational study

746

2-[N1-2-Pyrimidyl-aminobenzenesulfonamido] ethyl 4-bis(2-chloroethyl) aminophenyl butyrate: A potent antitumor agent

747

2-{(1E)-[(E)-2-(2,6-Dichlorobenzylidene)hydrazin-1-ylidene]methyl}phenol: crystal structure, Hirshfeld surface analysis and computational study

748

2-{[1-(3,4-Dihydroxyphenyl)methylidene]amino}benzoic acid immobilized Amberlite XAD-16 as metal extractant

749

2-{2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist

750

2′,2′-Ligation demonstrates the thermal dependence of DNA-directed positional control

751

2′,3′,4′,5′-Tetraacetyl-N(3)-carboxymethylriboflavin derivatives: synthesis and fluorescence studies

752

2′,3′-Didehydro-2′,3′-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions

753

2′,5′-Oligoadenylate-peptide nucleic acids (2–5A-PNAs) activate RNase L Original Research Article

754

2′-Amino-2′-deoxy-N6-(1-naphthylmethyl)adenosine as Novel Scaffold for a Polymer-Assisted Amidation Protocol

755

2′-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer

756

2′-Carboxybenzyl glycosides: glycosyl donors for C-glycosylation and conversion into other glycosyl donors

757

2′-C-Methyluridine phosphoramidite: a new building block for the preparation of RNA analogues carrying the 2′-hydroxyl group

758

2′-Deoxy-2′(S)-ethinyl oligonucleotides: A modification which selectively stabilizes oligoadenylate pairing to DNA complements

759

2′-deoxy-8-(propyn-1-yl)adenosine-containing oligonucleotides: effects on stability of duplex and quadruplex structures

760

2′-Deoxyadenylyl-(3′→5′)-isodideoxyadenosine, a unique dinucleotide: Synthesis, enzymology, and conformational studies

761

2′-deoxycytidine in free nucleosides and double-stranded dna as the major target of lipid peroxidation products

762

2′-deoxyguanosine oxidation is associated with decrease in the DNA-binding activity of the transcription factor Sp1 in liver and kidney from diabetic and insulin-resistant rats

763

2′-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: A novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1

764

2′-Fluoro Substituents Can Mimic Native 2′-Hydroxyls within Structured RNA

765

2′-Fluoro-3-deazaaristeromycin

766

2′-Hydroxyflavylium: introducing flavanones into the flavylium network of chemical reactions

767

2′-Lipid-modified oligonucleotides via a ‘Staudinger–Vilarrasa’ reaction

768

2′-Methyl and 1′-xylosyl derivatives of 2′-hydroxyflexixanthin are major carotenoids of Hymenobacter species

769

2′-Methyl taxanes: synthesis and NMR configurational assignment

770

2′-Nitroflavone induces cell cycle arrest and apoptosis in HeLa human cervical carcinoma cells

771

2′-O,4′-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug

772

2′-O,4′-C-methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties Original Research Article

773

2′-O-{[2,2-dimethyl-2-(2-nitrophenyl) acetyl] oxy} methyl protecting group for RNA synthesis

774

2′-O-Carbamate-containing oligonucleotides: synthesis and properties

775

2″-O-Glucosylvitexin, a chemotaxonomic marker for the genus Cryptocoryne (Araceae)

776

2″-Substituted 5-phenylterbenzimidazoles as topoisomerase I poisons Original Research Article

777

2+1 dimensional charged black hole with (anti-)self dual Maxwell fields

778

2+1 resonance-enhanced multiphoton ionisation spectroscopy of the high ν2 levels of the B̃1E″ Rydberg state of NH3(ND3)

779

2+1+1 two-color REMPI study of the E1Π(ν=1)←D1Δ(ν=10)←X1Σ+(ν=0) transition in CO: influence of the accidental predissociation in the CO E1Π(ν=1) state at j=9 and 10

780

2+2 may (or may not) yield 4

781

2× oversampling 2.5 Gbps clock and data recovery with phase picking method

782

2×2 superlattices

783

2×2 systems of conservation laws with L∞ data

784

2×CO2 Eastern Asia regional responses in the RSM/CCM3 modeling system

785

2·5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy

786

20 000 brains removed and retained without relativesʹ consent

787

20 Isometric strength of the small tears of the rotator cuff

788

20 K Energy storage unit Original Research Article

789

20 million contract

790

20 Mini vs. open repair of isolated supraspinatus tendon tears

791

20 most-cited countries in clinical medicine ranked by population size

792

20 Myr of eccentricity paced lacustrine cycles in the Cenozoic Ebro Basin

793

20 Pravastatin protects against development of chronic rejection in rat cardiac allografts and upregulates immunosuppressive TGF-B2

794

20 S proteasomes are imported as precursor complexes into the nucleus of yeast

795

20 Segment based interpolation revisited

796

20 thickened, fragile nails

797

20 years of active deformation on volcano caldera: Joint analysis of InSAR and AInSAR techniques

798

20 Years of Cardiac Resynchronization Therapy

799

20 years of experience in idiopathic central diabetes insipidus

800

20 years of mass balances on the Piloto glacier, Las Cuevas river basin, Mendoza, Argentina

801

20 years of patch testing with (meth)acrylates

802

20 years of scripted space

803

20% loss of unimproved farmland in 22 years in the Engadin, Swiss Alps

804

20% of sufferers could outgrow peanut allergy

805

20 My of nitrogen fixation during deposition of mid-Cretaceous black shales on the Demerara Rise, equatorial Atlantic Ocean

806

20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-κB in RAW 264.7 macrophages stimulated with lipopolysaccharide

807

20. Clinical and radiological predictors of complete excision in breast conserving treatment

808

20. Declining motor unit number estimates in a murine model of kennedy’s disease

809

20. Evaluation of oestrogen and progesterone receptors in breast cancer by comparing computer-assisted image analysis of immunocytochemical assay with enzyme immunoassay

810

20. Heart failure transition clinics: Can they reduce heart failure readmissions?

811

20. Heart failure… at home – sweet home

812

20. Multimodal intraoperative monitoring during spine surgery

813

20. rCBF measured by NIRS varies with the deep brain stimulation for STN

814

20/20 Foresight Crafting Strategy in an Uncertain World,: by Hugh Courtney, Harvard Business School Press, Boston, Massachusetts, 2001. ISBN 1-57851-266-2.

815

20/sup st/ century engineer-entrepreneur

816

20: A Comparison of Endotracheal Intubation Success Rates Between Providers of a Metropolitan Air Medical Transport Service

817

20: CT Coronary Angiography During Initial Visit Decreases Rate of Return Visits Relative To Standard Care

818

200 junior doctors sacked in Zambia

819

200 MeV Ag+15 ion irradiation created columnar defects and enhanced critical current density of La-2125 type superconducting thin films

820

200 MeV Ag15+ ion induced surface modification and transport behaviour in manganite based thin film devices

821

200 Years of British Hydrogeology, Mather J.D. (Ed.). Geological Society, London (2004), 394

822

200 years of practical electroanalytical chemistry: past, present and future directions illustrated by reference to the on-line, on-stream and off-line determination of trace metals in zinc plant electrolyte by voltammetric and potentiometric techniques O

823

200 000 yr diatom records from Atlantic upwelling sites reveal maximum productivity during LGM and a shift in phytoplankton community structure at 185 000 yr

824

2000 ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: A practical summary for emergency physicians

825

2000 ACM Conference on Intelligent User Interfaces

826

2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System

827

2000 John Cedric Griffiths teaching award of the international association for mathematical geology

828

2000 Shanghai Magnolia Award

829

2000 to 2015: How Far Have We Progressed in Achieving the Health Related Millennium Development Goals?

830

2000 years of sustainable use of watersheds and coral reefs in Pacific Islands: A review for Palau

831

2000 ans de colmatage du port antique de Fréjus (Forum Julii), France : une double métamorphose littorale

832

2000 years of frequent turbidite activity in the Capbreton Canyon (Bay of Biscay)

833

200000 yr diatom records from Atlantic upwelling sites reveal maximum productivity during LGM and a shift in phytoplankton community structure at 185000 yr

834

2000–2003 real estate bubble in the UK but not in the USA

835

2000-Ma sulphide concretions from the `Productiveʹ Formation of the Pechenga Greenstone Belt, NW Russia: genetic history based on morphological and isotopic evidence

836

2000-year environmental history of a karstic lake in the Mediterranean Pre-Pyrenees: the Estanya lakes (Spain)

837

2001 – A Controversy

838

2001 Ambassador Award: Mid-Atlantic Chapter Society of Toxicology

839

2001 assessment of nutritional influences on risk for cataract

840

2001 Bhuj, India, Earthquake Engineering Seismoscope Recordings and Eastern North America Ground-Motion Attenuation Relations

841

2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia

842

2001 Consensus guidelines for the management of women with cervical intraepithelial neoplasia

843

2001 Cumulative article and author index volume 44, number 6

844

2001 Felix Chayes prize for excellence in research in mathematical petrology of the international association for mathematical geology

845

2001 flank eruption of the alkali- and volatile-rich primitive basalt responsible for Mount Etnaʹs evolution in the last three decades

846

2001 ISPMB discounts for Plant Molecular Biology

847

2001 Kumho Science International Award in Plant Molecular Biology and Biotechnology Award Presentation ceremony

848

2001 LCATS research award

849

2001 meeting Southern Thoracic Surgical Association

850

2001 transcatheter cardiovascular therapeutics

851

2001 transcatheter cardiovascular therapeutics

852

2001 transcatheter cardiovascular therapeutics

853

2001 UTS Society for Utopian studies conf

854

2001: A Veterinary Odyssey – Here and Now

855

2001—the year for health-research ethics to take centre stage?

856

2002 AA29: Earthʹs recurrent quasi-satellite?

857

2002 annual report of the American association of poison control centers toxic exposure surveillance system

858

2002 Elections in Pakistan: A Reappraisal

859

2002 Henry H. Storch Award

860

2002 Kuiper prize lecture: Dust Astronomy

861

2002 Kumho Science International Award in Plant Molecular Biology and Biotechnology

862

2002 Leonid storm fluxes and related orbital elements

863

2002 Reviewers List

864

2002 Rumelhart prizewinner

865

2002 St. Christopher lecture

866

2002 state of the science: Celebration of sharing

867

2002 summer fires in Lithuania: Impact on the Vilnius city air quality and the inhabitants health

868

2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: Implications for emergency department practice

869

2002 Winter Conference on Plasma Spectrochemistry: Scottsdale Arizona 6–12 January 2002

870

2002: the year of the ‘diversity – ecosystem function’ debate

871

2002-2008 Yılları Arasında Erzurum Bölgesinde Birinci ve İkinci Basamak Sağlık Hizmetlerinin Değerlendirilmesi

872

2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System ,

873

2003 Author index

874

2003 European Winter Conference: 2003 European Conference on Plasma Spectrochemistry January 12–17, 2003

875

2003 International Ash Utilization Symposium

876

2003 Kumbo Science International Award in Plant Molecular Biology and Biotechnology: Awardee is Xing-Wang Deng

877

2003 Kumho Science International Award in Plant Molecular Biology and Biotechnology

878

2003 LCATS Research Award: Robert P. Holley

879

2003 Meeting Southern Thoracic Surgical Association

880

2003 Performance Evaluation reviewers

881

882

2003 Space Cryogenics Workshop, 18–19 September 2003, Girdwood, Alaska

883

2003 Subject index

884

2003 transcatheter cardiovascular therapeutics

885

2003: A centennial of spinthariscope and scintillation counting

886

2004 American College of Cardiology/American Heart Association Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: Implications for Emergency Department Practice

887

2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System

888

2004 AONE Award winner profiles

889

2004 Author index

890

2004 Eurographics Symposium on Parallel Graphics and Visualization

891

2004 Henry H. Storch Award

892

2004 Indian Ocean tsunami inflow and outflow at Phuket, Thailand

893

2004 ISPMB membership renewals

894

2004 John Cedric Griffiths Teaching Award to Jack Schuenemeyer

895

2004 Meeting Southern Thoracic Surgical Association

896

2004 Optical Society of Americas Topical Meeting on Optical Interference Coatings: manufacturing problem

897

2004 pediatric emergency medicine recertification examination

898

2004 Performance Evaluation reviewers

899

2004 Presidential campaign messages: A functional analysis of press releases from President Bush and Senator Kerry

900

2004 Psychoneuroimmunology Research Meeting Abstracts 101–150

901

2004 Psychoneuroimmunology Research Meeting Abstracts 1–50

902

2004 Psychoneuroimmunology Research Meeting Abstracts 151–205

903

2004 Psychoneuroimmunology Research Meeting Abstracts 51–100

904

2004 sports medicine subspecialty certification and recertification examination

905

2004 State of the Science and Science to Practice

906

2004 Subject index

907

2004 Survey of United States architects on the subject of switchable glazings

908

2004–2005 Analytical Developments in Secondary Ion Mass Spectrometry

909

2005 Author index

910

2005 Best Paper Award Recipients: A Message from the Editor-in-Chief

911

2005 Call for Papers

912

2005 IEEE East-West Design and Test Workshop

913

2005 IEEE/WIC/ACM International Joint Conference on Web Intelligence and Intelligent Agent Technology (WI-IAT’05)

914

2005 Kumho award recipient

915

2005 List of reviewers for Automatica

916

2005 Meeting Southern Thoracic Surgical Association

917

2005 Photometric observations and multiple frequencies of the δ Scuti variable CC And

918

919

2005 State of the Future (Millennium Project), American Council for the United Nations University (2005) plus CD-Rom.

920

2005 Subject index

921

2005 was a good year for Japanʹs carbon black industry

922

2006 ACS Award Issue “For Creative Work in Fluorine Chemistry” Kenji Uneyama

923

2006 Acta Materialia, Inc. Gold Medal

924

2006 Acta Materialia, Inc. J. Herbert Hollomon Award

925

2006 clinical immunology school on systemic autoimmune diseases

926

2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests

927

2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ

928

2006 Eurographics Symposium on Parallel Graphics and Visualization

929

2006 Fragmentation of Comet 73P/Schwassmann-Wachmann 3B observed with Subaru/Suprime-Cam

930

2006 Gondwana Research Best Paper Award

931

2006 Henry H. Storch Award in Fuel Chemistry goes to Colin Snape

932

2006 International symposium on biomedical engineering, Taiwan (2006-ISOBME)

933

2006 John Cedric Griffiths Teaching Award to Paul Switzer

934

2006 Latin American Test Workshop

935

2006 list of reviewers for Automatica

936

2006 Meeting Southern Thoracic Surgical Association

937

2006 Performance Evaluation reviewers

938

2006 Research Award

939

940

2006 Reviewers List (PDF)

941

2006 Sarawak State Elections: Issues and Electoral Results

942

2007 Acta Materialia, Inc. Gold Medal

943

2007 Annual meeting of the Society of Urologic Oncology and the Society of Basic Urologic Research: Introduction

944

2007 Award of Merit Acceptance Speech

945

2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Devel

946

2007 Editorsʹ Collection

947

2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction Review Article

948

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention Review Article

949

2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings

950

2007 Henry H. Storch Award in Fuel Chemistry goes to Ronald J. Pugmire

951

2007 Index IEEE Transactions On Nanotechnology Vol. 6

952

2007 list of reviewers for Automatica

953

2007 Mutual events within the binary system of (22) Kalliope

954

955

2007 SEI and ASCE Structural Awards

956

2007 Space Cryogenics Workshop

957

2007 will be a highlight in the life of the International Institute of Refrigeration

958

2007 Counselling Psychology in India: At the Confluence of Two Traditions

959

2007-2008 Discussions on Predictability of The Global Financial Crisis

960

2008 ACS Award Issue “For Creative Work in Fluorine Chemistry”, Dennis P. Curran

961

2008 Acta Materialia, Inc. J. Herbert Hollomon Award

962

2008 Australian Organic Geochemistry Conference. A national conference held in association with the International Humic Substances Society and the Natural Organic Matter Interest Group

963

2008 Benjamin Franklin medal in life science is Presented to Victor Ambros, Ph.D. (University of Massachusetts Medical School, Worcester, Massachusetts), Gary Ruvkun, Ph.D. (Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts) an

964

2008 Bower Award and Prize for Achievement in Science

965

2008 Economics Crisis in Malaysia: Implications on the Economy,Society and Safety Nets

966

2008 Editorsʹ Collection

967

2008 Fuel Chemistry Division Storch Award

968

2008 General Elections in Malaysia: Democracy at Work

969

2008 General Elections in Malaysia: Democracy at Work

970

2008 Gondwana Research Best Paper Award

971

972

2008 John Cedric Griffiths Teaching Award to Vera Pawlowsky

973

2008 list of reviewers for Automatica

974

975

2008 Whitmore Lecture: Radical prostatectomy—where we were and where we are going

976

2009 ACCF/AHA Focused Update on Perioperative Beta Blockade

977

2009 Acta Materialia, Inc. Gold Medal Award

978

2009 Acta Materialia, Inc. Materials & Society Award (Formerly the J. Herbert Holloman Award)

979

2009 CALPHAD Awards

980

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With th

981

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guid

982

2009 IAGR Annual Convention and 6th International Symposium on Gondwana to Asia

983

984

2009 list of reviewers for Automatica

985

2009 Quality survey of retail biodiesel blends in Michigan

986

2009 Space Cryogenics Workshop

987

2009 Summer Forum for Present and Future of HIFU Treatment on Gynecological Diseases held in Chongqing, P.R. China (18–24 July 2009)

988

2009 Summer Forum for Present and Future of HIFU Treatment on Gynecological Diseases held in Chongqing, P.R. China (18–24 July 2009)

989

200-MeV bremsstrahlung tagged photon beams at Sendai

990

200-MeV bremsstrahlung tagged photon beams at Sendai

991

200-mW-Average Power Ultraviolet Generation at 0.193 (mu)m in K2Al2B2O7

992

2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With

993

2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease: Executive Summary

994

2010 Acta Biomaterialia Gold Medal

995

2010 Acta Materialia Materials and Society Award

996

2010 Acta Materialia, Inc. Gold Medal Award

997

2010 ASIS&T James M. Cretsos Leadership Award

998

2010 IAGR Annual Convention and 7th International Symposium on Gondwana to Asia

999

2010 Labour Party Leadership Election

1000

2010 list of reviewers for Automatica

بازگشت